özgeçmiş ve eserler listesi

Transkript

ÖZGEÇMİŞ VE ESERLER LİSTESİ
ÖZGEÇMİŞ
1.1 Adı Soyadı: NAZIM SERDAR TURHAL
1.2 Doğum Tarihi: 05 NİSAN 1964
1.3. Öğrenim Durumu:
Bölüm/Program
Derece
Üniversite
Yıl
Tıp Doktoru
Cerrahpaşa Tıp Fakültesi
İstanbul Üniversitesi
1987
Tıpta Uzmanlık
Griffin Hastanesi İç Hastalıkları
Ana Bilim Dalı
Yale Üniversitesi
1993
Mount Sinai Tıp Fakültesi
Tıbbi Onkoloji
Hematoloji – Onkoloji Bilim
Uzmanlığı
Dalı
Mount Sinai Tıp Fakültesi,
1997
New York, New York, ABD
1.3.1 Lisans:
1.4. Görevler:
Görev Yeri
Görev Unvanı
Uzm. Dr.
Marmara Üniversitesi Tıp Fakültesi
Yıl
1997 - 1998
İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı
Yrd. Doç. Dr.
1998 - 1999
Doç. Dr.
1999 - 2006
Prof. Dr.
2006 -
1.5. Aldığı Ödüller :
1.5.1 American Colloege of Physicians “Certificate of Merit” Mayıs 1993 Connecticut,
USA
1.5.2 SOMPS 2001, Best poster/presentation award. Outcome of patients after
adjuvant treatment for breast cancer. Atalay G, Turhal NS. 11th International
Congress on Anti-Cancer Treatment (ICACT), February 6-9, 2001, Paris, France
1.5.3 Atasoy BM, Abacıoğlu U, Özgen Z, Dane F, Yumuk F, Mayadağlı A, Turhal
NS, Şengöz M, “Rektum Kanserinin adjuvan tedavisinde radyoterapiyle eş zamanlı
Tegafur-Urasil (UFT)/Folinik asit (FA) uygulanması: Tolerabilite Değerlendirilmesi,”
1. Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, SB46 (Sözlü Sunum), Antalya, 29
Mart - 2 Nisan 2006. [Sözlü Sunum Ödülü]
1
1.5.4 Dane F, Gümüş M, Öztürk MA, Atasoy BM, İyikesici S, Yumuk PF, Başaran G,
Abacıoğlu U, Çabuk DÖ, Teomete M, Turhal NS, “Rektum Kanseri Olgularının
Klinik Özellikleri ve Adjuvan Kemoradyoterapi Sonuçları: Tek Merkez Tecrübesi,”
2.Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, P23, Antalya, 2008. [Poster Bildiri
Ödülü]
1.5.5 Dane F, Gümüş M, Yaman E, Öztürk MA, Sevinç A, Atasoy BM, Çabuk D,
İyikesici S, Yumuk PF, Başaran GA, Abacıoğlu U, Teomete M, Turhal NS. Küratif
olarak rezeke edilmiş evre II-III rektum kanserli Türk hasta popülasyonunun
adjuvan kemoradyoterapi sonuçları, prognostik özellikleri ve sağkalım analizleri,
çok merkezli retrospektif çalışma. Marmara Üniversitesi Tıp Fakültesi 4. Araştırma
Günleri, Marmara Medical Journal, 22(1, Ek 1), 9, İstanbul, 2009, [En İyi Bildiri
Ödülü].
1.5.6 Basaran G, Cabuk D, Korkmaz T, Kocar M, Telli F, Dane F, Yumuk F, Turhal
NS.Clinical, pathological factors predicting early relapse in hormone receptor early
breast cancer. BUON Congress 2010, Best Abstracts Presented at BUON
Congress 2010, 8-11 September 2010, Sibiu, Romania
1.5.7 Ozturk MA, Dane F, Karagoz S, Tural D, Demirelli F, Basaran G, Buyukunal
E, Mandel NM, Erdamar S, Turna H, Seber S, Turhal NS, Serdengecti S. The
prognostic value of perineural invasion in patients with early stage colon cancer.
BUON Congress 2010, Best Abstracts Presented at BUON Congress 2010,
Proceedings Book, 8-11 September 2010, Sibiu, Romania. BA 65, page 23
1.6. Aldığı Burslar:
European School of Medical Oncology Technology Transfer Grant 2000
2
1.7. Üyesi Olduğu Meslek Kuruluşları:
Türk Tabipler Birliği
Türk Onkoloji Grubu
Türk Onkoloji Derneği
American College of Physicians
Balkan Union of Oncology
European Society of Medical Oncology
American Society of Clinical Oncology
1997
1997
1997
1998
1998
1999
1999
1.8. Yeterlilik Kurulu Üyeliği:
Türk Onkoloji Derneği
2007
3
1.8. Lisans ve Lisans üstü eğitimde verdiği dersler:
Akademik
Yıl
Haftalık Saati
Dönem
Güz
2002-2003
İlkbahar
Dersin Adı
Öğrenci
Sayısı
Teorik
Uygulama
Marmara Üniversitesi Tıp
Fakültesi Dönem 4 İç
Hastalıkları Stajı
2
4
55
Hastalıkları Stajı Tıbbi Onkoloji
Rotasyonu (birer ay)
2
10
4
Fakültesi Tıpta Uzmanlık
Öğrencileri Tıbbi Onkoloji
2
10
4
Öğrencileri Eğitim Programı
2
-
34
Fakültesi Tıbbi Onkoloji Yan
Dal Uzmanlığı Eğitim Programı
2
10
3
2
4
55
2
10
4
2
10
4
1
-
34
2
10
3
2
4
55
4
Güz
2003-2007
İlkbahar
2
10
4
2
10
4
2
-
34
2
10
3
2
4
55
2
10
4
2
10
4
1
-
34
2
10
3
5
1.9. Yönettiği tamamlanmış tezler:
1-
Primer meme kanserinin saptanmasında teknezyum 99m-metilendifosfonat
mamosintigrafisinin in vivo kullanımı
Dr. Faysal Dane, İstanbul – 2002
2-
Meme kanserli hastalarda normal ve tümöral doku örneklerinde human papilloma
virüs(HPV) DNA sıklığı ve HPV tip tayini
Dr. Mahmut Gümüş, İstanbul – 2003
3-
Evre II – III kolorektal kanserlerde timidilat sentetaz ve COX-2’nin prognostik faktör
olarak incelenmesi.
Uzm. Dr. Mehmet Aliustaoğlu, İstanbul – 2003
4-
Mide kanserinde bağışıklık yanıtının anjiogenezin ve sekonder lenfoid doku
kemokin ekspresyonunun değerlendirilmesi
Dr. Meltem Ekenel, İstanbul – 2005
5-
Mide kanserinde HIF-1 Alfa, Vegf ekspresyonu ve bu faktörlelrin prognostik önemi.
Dr. Devrim Özcan Çabuk, İstanbul – 2006
6-
Unrezektabl evre III ve evre IV küçük hücreli dışı akciğer kanseri tanılı kadın
hastaların klinik özellikleri ve sağkalım analizleri
Uzm Dr Mehmet Teomete, İstanbul – 2008
1.11. Yönetim Hizmetleri:
Onkoloji Bilim Dalı Başkanı 1997 1.12. Üniversite içinde ve / veya dışında eğitim, öğretim, araştırma, geliştirme, üretim
alanlarında yöneticilik veya kuruculuk yapmış olmak:
1. Avrupa Kanser Araştırma Birliği Mide Kanseri Araştırma Kurulu Kurucu Üyesi
2. BİKİMER Marmara Üniversitesi Bilimsel Araştırma Komisyonu Kanser Araştırma
Grubu Kurucu Üyesi
1.13. Hakemlik veya yayın danışma kurulu üyeliği:
1.13.1. Makale hakemliği
1. Türkiye Klinikleri Tıp Bilimleri Dergisi
2. Kartal Eğitim Araştırma Hastanesi Tıp Dergisi
3. Turkish Journal of Cancer
4. International Journal of Experimental and Clinical Chemotherapy
5. Biomed Central, Cancer
1.13.2. Yayın kurulu üyeliği
1. Turkish Journal of Cancer
6
2. ACTA Oncologica Turkish Edition
3. Kartal Eğitim Araştırma Hastanesi Tıp Dergisi
4. Türkiye Klinikleri Tıp Bilimleri Dergisi
5. British Journal of Cancer
7
2. BİLİMSEL ÇALIŞMALAR:
2.1. Doktora veya İhtisas Tezi:
Mide Kanseri için yeni peri adjuvan tedavi stratejileri.
Tez Danışmanı: Prof. Dr. Howard Bruckner, Mount Sinai Tıp Fakültesi
İleri safha pankreas kanserinde kombine tedavi uygulaması ve uzun dönemli takibi.
Tez Danışmanı: Prof. Dr. Howard Bruckner, Mount Sinai Tıp Fakültesi
2.2. Doktora veya ihtisas tezinden yayınlanmış makaleler:
A. DOÇENTLİK ÖNCESİ
2.2.1. Turhal NS, Bruckner HW. “New neoadjuvant treatment strategies for gastric and
gastroesophageal junction cancers”, Marmara Medical Journal 1999 12(1): 20-24.
2.2.2. Turhal NS, Terk M, Bruckner HW. “Combined Modality Therapy for Pancreatic
Cancer”. Turkish Journal of Cancer, 1999 11(2): 55-64.
2.3. Doktora veya ihtisas tezi dışında yayınlanmış makaleler:
2.3.1. Uluslararası hakemli dergilerde yayımlanan makaleler :
2.3.1.1. Turhal N, Sullivan MB, Blakemore WS. Thyroglossal Duct Cyst. South Med J,
1990, 83:8, 983-4.
Atıflar: 2 adet
2.3.1.2. Turhal N, DeLuca VA Jr. Ulcerative Colitis and Scleroderma. A coincidental
relationship. J Clin Gastroenterol. 1994, 18:3, 218-9.
Atıflar: 1 adet
http://scholar.google.com.tr/scholar?hl=tr&lr=&cites=14087877503050283226
2.3.1.3. Turhal NS, Henehan MD, Kaplan KL. Multiple myeloma: a patient with unusual
features including intracranial and meningeal involvement, testicular involvement,
organomegaly, and plasma cell leukemia. Am J Hematol 1998, 57:1, 51-56.
Atıflar: 5 adet
2.3.1.4. Turhal NS. Cyclosporin A and Imipenem Associated Seizure Activity in
Allogeneic Bone Marrow Transplantation Patients. Journal of Chemotherapy 1999 11(5):
410-413.
Atıflar: 1 adet
8
B. DOÇENTLİK SONRASI
2.3.1.5. Turhal NS, Erdal S, Karacay S. Efficacy of the Treatment to Relieve Mucositis
Induced Discomfort. Supportive Care in Cancer 2000 8(1): 55-58.
Atıflar: 11 adet
2.3.1.6. Turhal NS. Pancreatic Duct Cell Carcinoma with Positive In-111 Octreotide
Uptake. Journal of Experimental and Clinical Cancer Research 2000 19(2): 241-244.
Atıflar: 1 adet
2.3.1.7. Turhal NS. Sumatriptan overdose in episodic cluster headache: a case report of
overuse without event. Cephalalgia. 2001 21:700.
Atıflar: 2 adet
2.3.1.8. Turhal NS, Rand J. Antiphospholipid syndrome in HIV infection - Report of four
cases and review of literature. Allergy & Clinical Immunology International 2001 13(6):14.
Atıflar: 4 adet
2.3.1.9. Duman D, Turhal NS, Duman DG, M.D. Fatal Aplastic Anemia during Treatment
with Ketoconazole. American Journal of Medicine 2001, 111:9
Atıflar: 2 Adet
2.3.1.10. Turhal NS. Two cases of advanced renal cell cancer with prolonged survival of
8 and 12 years. Japanese Journal of Clinical Oncology 2002 32(4): 152-153
Atıflar: 1 Adet
2.3.1.11. Turhal NS, Gumus M, Atalay G, Aliustaoglu M, Kabakas F, Karamanoglu A,
Sengoz M. Outpatient cancer care in a Turkish university hospital. Journal of BUON 2002
7(4): 397-398.
2.3.1.12. Turhal NS, Efe B, Gumus M, Aliustaoglu M, Karamanoglu A, Sengoz M. Patient
satisfaction in the outpatients` chemotherapy unit of Marmara University, Istanbul,
Turkey: a staff survey. BMC Cancer 2002 2(1): 30-33.
Atıflar: 1 adet
2.3.1.13. Turhal NS, Aliustaoglu M, Gurses I, Gumus M, Atalay G, Karamanoglu A,
Sengoz M. Neoplastic diseases prevalence in a Turkish university hospital. Journal of
BUON 2003 8(1): 45-48.
2.3.1.14. Karamanoglu A, Yumuk PF, Gumus M, Aliustaoglu M, Selimen D, Sengoz M,
Turhal NS. Port needles: Do they need to be removed as frequently in infusional
chemotherapy? Journal of Infusional Nursing 2003 26(4):239-242.
9
Atıflar: 3 Adet
2.3.1.15. Abacıoglu U, Sengoz M, Yumuk F, Salepci T, Turhal NS. Cisplatin and
etoposide in extra pulmonary small cell cancer. Tumori 2003 89(3): 274-277.
Atıflar: 20 adet
2.3.1.16. Yumuk PF, Abacioglu U, Caglar H, Gumus M, Sengoz M, Turhal NS. Outcome
of rectum and sigmoid carcinoma patients receiving adjuvant chemoradiotherapy in
Marmara University Hospital. J Chemother 15 (6): 603-606, 2003.
2.3.1.17. Turhal NS, Dane F, Dede F, Gumus M, Yumuk PF, Cakalagaoglu F, Savcı D,
Karaman M, Gulluoglu B, Turoglu HT. 99m-Tc-MDP Scintimammography to assess
angiogenesis in patients with untreated breast cancer. Anticancer Research. 24:19992006 (2004)
Atıflar: 1 Adet
2.3.1.18. Yumuk PF, Gumus M, Ekenel M, Basaran G, Aliustaoglu M, Topal A, Turhal
NS, N. Attitude Toward Genetic Testing in Turkish Society. Genetic Testing 8(2):169-173,
2004
Atıflar: 2 Adet
2.3.1.19. Yumuk PF, Aydin SZ, Dane F, Gumus M, Ekenel M, Aliustaoglu M,
Karamanoglu A, Sengoz M, Turhal NS. The absence of early diarrhea with atropine
premedication during irinotecan therapy in metastatic colorectal patients. International
Journal of Colorectal Disease 19: 609-610, 2004.
Atıflar: 1 Adet
2.3.1.20. Bolukbas FF, Kılıc H, Bolukbas C, Gumus M, Horoz M, Turhal NS, Kavalı B.
Serum leptin concentration and advanced gastrointestinal cancers: a case controlled
study. BMC Cancer 2004, 4:29-32.
Atıflar: 7 Adet
2.3.1.21. Yumuk PF, Abacioglu U, Demir G, Cabuk D, Dane F, Gumus M, Ozguroglu M,
Ekenel M, Basaran G, Turhal NS. Does the Incidence of Anal Canal Cancers Differ in
Moslem Societies? International Journal of Colorectal Disease, Clinical and Molecular
Gastroenterology and Surgery. 20(1), 76 2004.
2.3.1.22. Aliustaoglu M, Yumuk PF,Gumus M, Ekenel M, Bolukbas F, Mutlu N, Basaran
G, Avsar E, Turhal NS. D-Dimer—Can it be a marker for malignant gastric lesions. Acta
Oncologica, 2004 Dec 43(8) 770-771.
Atıflar: 2 Adet
2.3.1.23. Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J,
Koller M, Turhal NS, Stuart R, Van Cutsem E, D’Haese S, Coens C. Clinical and
10
Psychometric validation of a questionnaire module, The EORTC QLQ-STO 22, to assess
quality of life in patients with gastric cancer. Eur J Cancer, 2004 Oct 40(15): 2260-8
Atıflar: 13 Adet
2.3.1.24. Gumus M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar
H, Sengoz M, Turhal S. What should be the optimal number of lymph nodes dissected in
colorectal Cancer surgery? Tumori, 172/03. 11 2004.
PROFESÖRLÜK SONRASI
2.3.1.25. Yumuk PF, Turhal NS, Gumus M, Hatabay NF, Turken O, Ozkan A, Salepci T,
Aliustaoglu M, Ahiskali R, “Results of paclitaxel (day 1 and 8) and Carboplatin given on
every three weeks in advanced (stage III-IV) non-small cell lung Cancer”, BMC Cancer,
(MS:7372801141679098), 2005 March, 21
2.3.1.26. Abacioğlu U, Yumuk PF, Caglar H, Sengoz M, Turhal NS, “Concurrent
chemoradiotherapy with low dose weekly Gemcitabine in stage III non-small cell lung
cancer.” BMC Cancer. 2005 Jul, 6;5:71
Atıflar: 3 Adet
2.3.1.27. Yumuk PF, Turhal NS, Gumus M, Hatabay NF, Turken O, Ozkan A, Salepci T,
Aliustaoglu M, Ahiskali R. Results of Paclitaxel (day 1 and 8) and carboplatingiven on
every three weeks in advanced (stage III-IV) non-small cell lung cancer. BMC Cancer.
2005 Jan 25;5:10.
2.3.1.28. Yumuk PF, Abacioglu U, Demir G, Cabuk D, Dane F, Gumus M, Ozguroglu M,
Ekenel M, Basaran G, Turhal NS, Does the incidence of anal canal cancers differ in
Moslem societes? International Journal of Colorectal Disease 2005 20:76
2.3.1.29. Turhal NS, Popov I. Colorectal cancer care in the Balkan countries. Journal of
Balkan Union of Oncology Volume 10 No: 2, April-June 2005 189-193
2.3.1.30. Gumus M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar
H, Sengoz M, Turhal NS, What is the optimal number of lymph nodes to be dissected in
colorectal cancer surgery? Tumori. 2005 Mar-Apr;91(2): 168-72
Atıflar: 5 Adet
2.3.1.31. Abacioglu U, Yumuk PF, Caglar H, Sengoz M, Turhal NS, Concurrent
chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung
cancer. BMC Cancer, 2005 Jul 6;5:71
2.3.1.32. Onol FF, Tanidir Y, Kotiloglu E, Bayramicli M, Turhal NS, Turkeri LN. “Proximal
type epithelioid sarcoma of the scrotum: a source of diagnostic confusion that needs
immediate attention.” Eur Urol. 2006 Feb; 49(2):7. Epub 2005 Nov 7.
Atıflar: 2 Adet
11
2.3.1.33. Turhal NS, Popov IP. “Colorectal cancer care in the Balkan countries.” J BUON
2005 Apr-Jun;10(2):189-93
2.3.1.34. Onol FF, Tanidir Y, Kotiloglu E, Bayramicli M, Turhal NS, Turkeri LN. “Proximal
immediate attention: Part 2.” Eur Urol 2006 Mar 49(3):578-80.
2.3.1.35 Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, Basaran G,
Kaya H, Barisik N, Turhal NS. “HPV DNA frequency and subset analysis in human
breast cancer patients normal and tumoral tissue samples.” J Exp Clin Cancer Res. 2006
Dec;25(4):515-21.
2.3.1.36. Onol FF, Tandr Y, Kotiloglu E, Bayramicli M, Turhal NS, Turkeri LN. Proximal
immediate attention. Part 1: Eur Urol 2006 Feb;49(2): 406-7
2.3.1.37. Onol FF, Tandr Y, Kotiloglu E, Bayramicli M, Turhal NS, Turkeri LN. Proximal
immediate attention. Part 2: Eur Urol. 2006 Mar; 49(3):578-80.
2.3.1.38. Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, Basaran G,
Kaya H, Barisik N, Turhal NS. HPV DNA frequency and subset analysis in human breast
cancer patients normal and tumoral tissue samples. Journal of Experimental and Clinical
Cancer Research, December 2006, 515-521
Atıflar: 7 Adet
2.3.1.39. Komurcu S, Turhal NS, Altundag K, Atahan L, Turna HS, Manavoglu O, Yavuz
AA, Ozkok S, Aliustaoglu M, Altinbas M, Pak Y, Cooper R, Yaylaci M, Demirkan B,
Sarihan S, Ozdemir F. “Safety and efficacy of transdermal fentanyl in patients with cancer
pain: phase IV, Turkish Oncology group trial.” Eur J Cancer Care (Engl). 2007 Jan;
16(1):67-73
2.3.1.40. Atasoy BM, Abacioglu U, Dane F, Ozgen Z, Yumuk PF, Ozden S, Akgun Z,
Mayadagli A, Basaran G, Turhal NS, Sengoz M. “Concomitant administration of uraciltegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer.” J
BUON. 2007 Apr-Jun;12(2):203-8.
Atıflar: 1 Adet
2.3.1.41. Celikel C, Eren F, Gulluoglu B, Bekiroglu N, Turhal NS. “Relation of
neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor
receptor expression in gastric adenocarcinomas: prognostic implications.” Pathol Oncol
Res. 2007:13(3):215-26. Epub 2007 Oct 7.
2.3.1.42. Cabuk D, Basaran G, Celikel C, Dane F, Yumuk PF, Iyikesici MS, Ekenel M,
Turhal NS. “Vascular Endothelial Growth Factor, Hypoxia-Inducible Factor 1 Alpha and
12
CD34 Expressions in Early-Stage Gastric Tumors: Relationship with Pathological Factors
and Prognostic Impact on Survival.” Oncology. 2007 Nov 15;72(1-2):111-117.
Atıflar: 1 Adet
2.3.1.43. Atasoy BM, Abacioglu U, Dane F, Ozgen Z, Yumuk PF, Ozden S, Akgun Z,
Mayadagli A, Basaran G, Turhal NS, Sengoz M. Concomitant administration of uraciltegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer.
Journal of BUON 12: 203-208, 2007
2.3.1.44. Yumuk PF, Dane F, Yumuk VD, Yazici D, Ege B, Bekiroglu N, Toprak A,
Iyikesici S, Basaran G, Turhal NS.Impact of body mass index on cancer development. J
BUON. 2008 Jan-Mar;13(1):55-59
2.3.1.45. Atasoy BM, Dane F, Yumuk PF, Akgün Z, Turhal NS, Abacioğlu U, Sengöz M.
Toxicity and feasibility analysis for cisplatin-based concomitant chemoradiotherapy in
locally advanced nasopharyngeal carcinoma. J BUON. 2008 Jan-Mar;13(1):43-50.
2.3.1.46. Koldas M, Gumus M, Seker M, Seval H, Huyla K, Dane F, Kural A, Gumus A,
Salepci T. and NS Turhal, ”Thrombin-activatable fibrinolysis inhibitor levels in patients
with non-small-cell lung cancer,” Clin Lung Cancer., 9(2), 112-115 (2008).
2.3.1.47. Ustaalioglu BB, Gumus M, Bilici A, Seker M, Dane F, Salepci T, S alman T,
Aliustaoglu M, Gezen C, Yaylaci M, Turhal NS, Neoadjuvant chemotherapy for locally
advanced breast cancer: a single center experience. Med. Oncol, 2009 Jun 2.
2.3.1.48. Kefeli U, Dane F, Yumu k PF, Karamanoglu A, Iyikesici M, Basaran G, Turhal
NS, Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous
implanted port care in patients with cancer. Eur J Cancer Care (Engl), 2009 Mar; 18(2),
191-4.
2.3.1.49. Kuscu MK, Dural U, Onen P, Yasa Y, Yayla M, Basaran G, Turhal NS,
Bekiroglu N. The association between individual attachment patterns, the perceived
social support, and the psychological well-being of Turkish informal caregivers.
Psychooncology, 2009 Jan 12.
2.3.1.50. Dane F, Ozturk MA, Tecimer T, Atasoy BM, Cabuk D, Yumuk PF, Basaran G,
Teomete M, Turhal NS. A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin’s
lymphoma: The importance of second opinion. J BUON, 2009 Apr-Jun;14(2):309-11.
2.3.1.51. Kefeli U, Dane F., Yumuk PF, Karamanoglu A, Iyikesici S, Basaran G, and NS
Turhal, “Prolonged inerval in prophylactic heparin flushing for maintenance of
subcutaneous implanted port care in patients with cancer,” Eur J Cancer Care (Engl),
18(2), 191-194 (2009).
2.3.1.52. Dane F, Ozturk MA, Tecimer T, Atasoy BM, Cabuk D, Yumuk PF, Basaran G,
Teomete M, and NS Turhal, “A case of Kikuchi-Fujimoto disease misdiagnosed as
Hodgkin’s lymphoma: the importance of second opinion,” J BUON, (2009). [basımda]
2.3.1.53. Gumus M, Basak O, Ustaalioglu MG, Kiziltan E, Bilici A, Seker M, Erkol B,
Salepci T, Mayadagli A, Turhal NS. Factors that Affect Patients’ Decision-Making about
Mastectomy or Breast Conserving Surgery, and the Psychological Effect of this Choice
on Breast Cancer Patients. Breast Care 2010;5:164–168
13
2.3.1.54. Dane F, Yumuk PF, Başaran G, Gündüz F, Peker Ö, Turhal NS, A Case of
Primary Breast Mantle Cell Lymphoma with Atypical Relapse Patterns and Rewiew of the
Literature Journal of BUON Vol: 16 No: 2, 2010
2.3.1.55. Turhal NS, Bas E, Er O, Aliustaoglu M, Seber S, Dane F, Korkmaz T, Soyuer I,
Ozkara S, Celikel C. ERCC1 is not expressed in hepatocellular cancer: A Turkish
Oncology Group, Gastrointestinal Oncology Subgroup study. Journal of BUON 15: 794796, 2010
2.3.1.56. Turhal NS. Dane F, Sınav H, Yalçın N, Khorshidi Z, Yalçın ZZ. Anxiety and
depression in Turkish breast cancer patients. Journal of BUON 15: 720-725, 2010
2.3.1.57. Korkmaz T, Seber S, Turhal NS. Primary melanoma of the gallbladder. Letter
802
2.3.1.58. Basaran G, Cabuk D, Caglar HB, Gulluoglu B, Kaya H, Seber S, Korkmaz T,
Telli F, Kocak M, Dane F, Yumuk PF, Turhal NS. Clinical outcome of breast cancer
patients with N3a (≥10 positive lymph nodes) disease: has it changed over years? Med
Oncol. 2010 Apr 14. [Epub ahead of print] DOI 10.1007/s12032-010-9516-1.
2.3.1.59. Dane F, Ozturk MA, Gumus M, Guven A, Aliustaoğlu M, Cabuk D, Teomete M,
Basaran G, Yumuk PF, Turhal NS. Effi cacy, safety and prognostic features of resected
colon carcinoma treated in “real world” practice: a retrospective cohort-study. Journal of
BUON 16: 257-264, 2011
2.3.1.60. Bilici A, Dane F, Seker M, Ustaalioglu BB, Aliustaoglu M, Temiz S, Gezen C,
Yavuzer D, Aksu G, Mayadagli A, Gumus M, Uygun K, Turhal NS. Is Subdivision of pT2
Tumors Superior to Lymph Node Metastasis for Predicting Survival of Patients with
Gastric Cancer? Review of 224 Patients from Four Centers. Digestive Diseases And
Scienses DOI: 10.1007/s10620-011-1721-z 2011.
2.3.1.61. Dane F, Akif Ozturk M, Gumus M, Guven A, Aliustaoglu M, Cabuk D, Teomete
M, Basaran G, Fulden Yumuk P, Turhal NS. Efficacy, safety and prognostic features of
resected colon carcinoma treated in "real world" practice: a retrospective cohort-study. J
BUON. 2011 Apr-Jun;16(2):257-64.
2.3.1.62. Basaran G, Devrim C, Caglar HB, Gulluoglu B, Kaya H,Seber S, Korkmaz T,
Telli, Kocar M, Dane F, Turhal NS. Clinical outcome of breast cancer patients with N3a
(≥10 positive lymph nodes) disease: has it changed over years? Medical Oncology:
Volume 28, Issue 3 (2011), Page 726-732.
2.3.1.63. Korkmaz T, Seber S, Basaran G, Yumuk PF, Dane F, Kocar M, Telli F, Turhal
NS. 5-Flourouracil–Induced Encephalopathy in Parkinson’s disease. International Journal
of Hematology and Oncology 2011 vol: 21 Num 1 Page(s): 001-003
2.3.1.64. Abali H, Ata A, Ozdogan M, Turhal NS, Cabuk D, Seyrek E, Coskun HS, Arik Z,
Erman M, Celik I. Frequency of comorbid illnesses in cancer patients in Turkey. Journal
of BUON 16: 557-560, 2011.
2.3.1.65. Turhal NS, Dane F, Butur S, Kocak M, Telli F, Seber S, Kanitez M, Aktas B,
Yumuk PF. Efforts to Validate the Applicability of Established Chemotherapy Treatment
in Turkish Cancer Patient. Pharmaceutica Analytica Acta. S14. 2011
2.3.1.66. Okutur K, Korkmaz T, Seber S, Dane F, İlhan M, Turnal NS, Demir G. Weekly
Docetaxel, Cisplatin and 5-Flourouracil in the first-line treatment of metastatic gastric
cancer. MOJ:1;35-40, 2011.
14
2.3.1.67. Turhal NS. Daily life of a Turkish Medical Oncologist. J Oncol Pract 8:164-166,
2012
2.3.1.68. Korkmaz T, Seber S, Okutur K, Basaran G, Yumuk F, Dane F, Oney T, Polat O,
Madenci O, Demir G, Turhal NS. Serum thymidine kinase 1 levels correlates with FDG
uptake and prognosis in patients with non small cell lung cancer. Biomarkers, 2012; Early
Online: 1–7 © 2012 Informa UK, Ltd.
2.3.1.69. Turhal NS et al. The Association between Socio-Demographic Parameters and
the Use of Complementary Interventions in Cancer Patients in Turkey A Turkish
Oncology Group Study. Journal of Cancer Therapeutics and Research, ISSN: 2049-7962,
Volume: 1, Issue: 1, 2012
2.3.1.70. Uncu D, Aksoy S, Cetin B, Yetisyigit T, Ozdemir N, Berk V, Dane F, İnal A,
Harputluoglu H, Budakoglu B, Koca D, Sevinc A, Cihan Ş, Durnalı AG, Ozkan M, Oztürk
M, Işıkdoğan A, Büyükberber S, Benekli M, Köş T, Alkış N, Karaca H, Turhal NS, Zengin
N. Anatolian Society of Medical Oncology. Results of Adjuvant FOLFOX regimens in
stage III. Colorectal Cancer Patients. Retrospective Analysis of 667 Patients. Oncology
2013.84:240–245
2.3.1.71. Korkmaz T, Seber S, Yavuzer D, Gumus M, Turhal NS. Primary renal
carcinoid: Treatment and prognosis. Critical Reviews in Oncology/Hematology-2013
ONCH-1712; No of pages 19.
2.3.1.72. Artac M, Turhal NS, Kocer M, Karabulut B, Bozcuk H, Yalcin S, Karaagac M,
Gunduz S, Isik N, Uygun K. Do high-risk features support the, use of adjuvant
chemotherapy in stage II colon cancer? A Turkish Oncology Group study. Tumori,
100:143-148, 2014
2.3.1.73. Kani HT, Siykhmbayev A, Demircan N, Banzragch M, Gunes Yegin E, Bicakci
Y, Aydin Y, Irmak R, Guney Duman D, Yumuk PF, Dane F, Turhal NS, Bekiroglu N,
Ozdogan OC. Benefıcıal Effect of Multıdıscıplınary approach on Survıval ın
Hepatocellular Carcınoma Patıents. Journal of Hepatology2014 vol 60. S215-S359, P577
2.3.1.74. Kocar M, Bozkurtlar E, Telli F, Turhal NS, Kaya H, Kocar H, Yumuk PF. PTEN
loss is not associated with trastuzumab resistance in metastatic breast cancer. JBUON
2014; 19(4): 900-905.
2.3.1.75. Yalcin S, Trad D, Yasser AK, Halawani H, Demir OG, Mall R, Meshcheryakov
A, Nasr F, Nosworthy A, Osinsky D, Tumanova A, Turhal NS, Tejpar S, Köhne CH.
Personalized treatment is beter than one treatment fits all in the management of patients
with mCRC: a consensus statement. Future Oncol 2014; 10(16), 2643-2657
2.3.1.76. Tanriverdi O, Yavuzsen T, Akman T, Senler FC, Taskoylu BY, Turhal NS,
Komurcu S, Cehreli R, Yaren A, Ozyilkan JCED: Your manuscript entitled The
perspective of non-oncologistphysicians on patients with metastatic cancer and palliative
care (ALONEStudy): a study of the Palliative Care Working Committee of the Turkish
Oncology Group (TOG). J Cancer Educ. 2015 Jun;30(2):253-9. doi: 10.1007/s13187-0150794-3. PMID: 25631655 [PubMed - in process]
2.3.1.77 Dede F, Civen H, Dane F, Aliustaoglu M, Turhal NS, Turoglu HT, İnanir S.
Carbon-14 urea breath test: does it work in patients with partial gastric resection? Ann
Nucl Med. 2015 Nov;29(9):786-91. doi: 10.1007/s12149-015-1005-3. Epub 2015 Jul 18.
PMID: 26187581 [PubMed - in process]
2.3.1.78. Ozturk MA, Dane F, Karagoz S, Tural D, Selcukbiricik F, Demirelli F, Buyukunal
E, Ozguroglu M, Turna H, Erdamar S, Celikel CA, Bozkurtlar EB, Yumuk PF, Mandel NM,
Turhal NS, Serdengecti S. Is perineural invasion (PN) a determinant of disease free
15
survival in early stage colorectal cancer? Hepatogastroenterology. 2015 JanFeb;62(137):59-64. PMID: 25911868 [PubMed - indexed for MEDLINE]
2.3.1.79. Ozturk MA, Dane F, Karagoz S, Tural D, Selcukbiricik F, Demirelli F, Buyukunal
E, Ozguroglu M, Turna H, Erdamar S, Celikel CA, Bozkurtlar EB, Yumuk PF, Mandel NM,
Turhal NS, Serdengecti S. Epidemiology of colorectal cancer in Turkey: A crosssectional disease registry study (A Turkish Oncology Group trial). Turk J Gastroenterol.
2015 Mar;26(2):145-53. doi: 10.5152/tjg.2015.5685. PMID: 25835113 [PubMed - indexed
for MEDLINE]
2.3.1.80. Tanriverdi O, Yavuzsen T, Turhal NS, Kilic D, Yalcin S, Ozkan A, Uzunoglu S, UysalSonmez O, Akman T, Aktas B, Ulger S, Babacan T, Komurcu S, Yaren A, Cay-Senler F.
Depression and socio-economical burden are more common in primary caregivers of patients
who are not aware of their cancer: TURQUOISE Study by the Palliative Care Working
Committee of the Turkish Oncology Group (TOG). Eur J Cancer Care (Engl). 2015 Mar 30. doi:
10.1111/ecc.12315. [Epub ahead of print] PMID: 25828949 [PubMed - as supplied by
publisher]
2.3.1.81. Tanriverdi O, Cay-Senler F, Yavuzsen T, Turhal NS, Akman T, Komurcu S, Cehreli
R, Ozyilkan O. Perspectives and practical applications of medical oncologists on defensive
medicine (SYSIPHUS study): a study of the Palliative Care Working Committee of the Turkish
Oncology Group (TOG). Med Oncol. 2015 Apr;32(4):106. doi: 10.1007/s12032-015-0555-5.
Epub 2015 Mar 7. PMID: 25750041 [PubMed - in process]
2.3.2. Ulusal hakemli dergilerde yayımlanan makaleler :
2.3.2.1. Turhal NS. “Metastatik meme kanseri yaygın kemik metastazlarında tedavi”,
Kanser Gündemi, Türkiye Kanserle Savaş Vakfı, 1998 3(3): 118-121.
2.3.2.2. Turhal NS. “Yetişkin kanser hastalarında transfüzyon tedavisi yaklaşımları”
Damla, Kan Merkezleri ve Transfüzyon Derneği Bülteni, 1998 22:4-7.
2.3.2.3. Turhal NS. “Meme kanserinin biyolojik tedavisinde: Herceptin, Academic
Hospital 1998 4:16-18.
2.3.2.4. Turhal NS, Tanju P, Pekin S. “Serviks kanseri etyolojisine yönelik standart ve
gelecek vadeden tarama yaklaşımları” Hekimler Birliği Vakfı, Türkiye Klinikleri,
Jinekolojik Obstetrik, 1999 9(3): 215-220.
2.3.2.5. Turhal NS, Akdas A. “Prostat kanserinde gen tedavisi uygulaması ve sorunları”
Üroloji Bülteni 1999 10(1): 5-11.
2.3.2.6. Turhal NS. “Lokal ileri evre meme kanserinde neoadjuvan ve adjuvan
16
kemoterapi” Hematoloji-Onkoloji, Güncel Derleme Dergisi, 2001 3(2):123-127.
2.3.2.7. Atalay G, Turhal NS. “Kanserli hastalarda ağrı dışı semptomların palyasyonu:
Hıçkırık, disfaji ve dispepsi” Hematoloji-Onkoloji, Güncel Derleme Dergisi, 2001, 3(3):
236-239.
2.3.2.8. Kaya H, Kotiloglu E, Sengoz M, Turhal S, Uneri C. “Aggressive fibromatosis: A
case report”. Journal of Marmara University Dental Faculty, 2001 Vol 4(3): 288-90.
2.3.2.9. Basaran G, Ekenel M, Demirkalem P, Cakır T, Gulluoglu B, Gumus M, Dane F,
Iyikesici S, Kaya H, Yumuk PF, Turhal NS. “Evre 1 (T1 N0 M0) Meme Kanseri: Patolojik
özellikler ve klinik sonuçlar”, Türk Onkoloji Dergisi, 2004 19(2):53-57.
2.3.2.10. Yumuk PF, İyikesici MS, Gumus M, Aliustaoglu M, Dane F, Basaran G, Ekenel
M, Abacıoglu U, Turhal NS. “Lokal ileri ve metastatik küçük hücreli dışı akciğer kanseri
hastalarının değerlendirilmesi, Marmara Üniverstesi deneyimi“, Türk Onkoloji Dergisi,
2004 19(3): 106-110.
2.3.2.11. Yumuk PF, Turhal NS. “Bir medikal onkolog perspektifinden muskuloskeletal
hastalıklarda nükleer tıp” Turkish Journal of Nuclear Medicine 2004, Baskıda
2.3.2.12. Atasoy BM, Dane F, Sarı M, Yumuk PF, Akgün Z, Turhal NS, Abacıoğlu U, ve
Şengöz M, “Lokal ileri evre skuamöz hücreli baş ve boyun kanserinde sisplatinle eş
zamanlı kemoradyoterapi: Yan etki ve uygulanabilirlik analizi,” Türk Onkoloji Dergisi, 23,
1-11 (2008).
2.3.2.13. Atasoy BM, Dane F, Çağlar H, Tezcanlı E, Cingi A, Abacıoğlu U, Turhal NS, ve
C Yeğen, “Rezeke edilebilir lokal ileri evre rektum kanserinde floroprimidin bazlı
kemoterapi ile eş zamanlı ameliyat öncesi radyoterapi,” Türk Onkoloji Dergisi, 23, 163-171
(2008).
2.3.2.14. Atasoy BM, Dane F, Kefeli AÜ, Caglar H, Cingi A, Turhal NS, Abacıoglu U,
Yegen C. Concomitant chemoradiotherapy with low-dose weekly Gemcitabine for
nonmetastatic unresectable pancreatic cancer. The Turkish Journal of Gastroenterology
2011;22(1):60-64
2.3.3. Yayınlarına yapılan atıflar (citation):
2.3.3.1. Author(s): Kim JH; Lee SH; Park J; Kim HY; Lee SI; Nam EM; Park JO; Kim K;
Jung CW; Im YH; Kang WK; Lee MH; Park K. Title: Extrapulmonary small-cell
carcinoma: a single-institution experience. Source: JAPANESE JOURNAL OF CLINICAL
ONCOLOGY 2004, Vol 34, Iss 5, pp 250-254
2.3.3.2. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, Liu Z, Tan D, Cheng L,
Hatem F, Huang J, Anthony S. Title: Small Cell Carcinoma of the Prostate: An
Immunohistochemical Study. Source: American Journal of Surgical Pathology.
30(6):705-712, June 2006
2.3.3.3. Author(s): D. Demellawy, A. Samkari, M. Sur, F. Denardi, S. Alowami. Title:
Primary small cell carcinoma of the cecum. Source: Annals of Diagnostic
Pathology, Volume 10, Issue 3, Pages 162-165
17
2.3.3.4. Author(s): Young HK, Ryuk K, Ghap JJ, Myung HR, Sang YH, Hyuk CK, Jin SJ,
Tae BS, Jong YO, Ki NL. Title: Extrapulmonary small-cell carcinoma of the liver Source:
Journal of Hepato-Biliary-Pancreatic Surgery Oct. 2004 Vol 11, Num 5,
2.3.3.5. Author(s): Vogelsang H., Siewert I.R. Title: Neuroendokrine Tumors of the
hindgut Source: Best Practice & Research Clinical Gastroenterology, Volume 19, Issue
5, Pages 739-751
2.3.3.6. Author(s): A. Ferlito, K. Devaney, A. Rinaldo Title: Neuroendocrine neoplasms
of the larynx: Advances in identification, understanding, and management Source: Oral
Oncology, Volume 42, Issue 8, Pages 770-788
2.3.3.7. Author(s): E. Kurt, C. Sezgin, T. Evrensel, U. Yalcinkaya, O. Kanat, A. Veral,
M. Demiray, M. Arslan, B. Karabulut, I. Ercan, E. Goker, O. Manavoglu Title: Therapy,
outcome and analysis of c-kit expression in patients with extrapulmonary small cell
carcinoma Source: International Journal of Clinical Practice; 2005; 59 (5), 537–543.
2.3.3.8. Author(s): Chen JW , Yuan L , Hu HH Title: Small cell undifferentiated
carcinoma in the epididymis Source: Chinese Medical Journal 2005; 118(16): 1402-1404
2.3.3.9. Author(s): Author(s): Vogelsang H., Siewert I.R. Title: Neuroendokrine
Tumoren des Kolons und Rektums, Mit Ausnahme der Appendix Source: MULTİ
MODALİTY TREATMENT RESULTS Onkologe 2004-10:1069-1078
2.3.3.10. Author(s): Kim KO; Lee HY; Riyu MH; Shin SJ; Kim MK; Lee KH; Hyun MS;
Bae HS; Ryoo HM. Title: Extrapulmonary small-cell carcinoma Source: J Korean Med.
Sci. 2006; 21: 833-7
2.3.3.11. Author(s): Lee SS; Lee JL; Riyu HM; Chang HM; Tae WK; Jung SL; Jang SJ;
Khang SK; Kang YK Title: Extrapulmonary small cell carcinoma: Single center
experience with 61 patients Source: Acta Oncologica, Volume 46, Issue 6 2007 , pages
846 – 851
2.3.3.12. Author(s): M. Yashi, F. Terauchi, A. Nukui, M. Ochi, M. Yuzawa, Y. Hara, T.
Morita Title: Small-cell neuroendocrine carcinoma as a variant form of prostate cancer
recurrence: A case report and short literature review Source: Urologic Oncology:
Seminars and Original Investigations, Volume 24, Issue 4, Pages 313-317
2.3.3.13. Author(s): A Barbeaux, L Duck, B Weynand, G Desuter, M Hamoir, V Gregoire,
J Baurain, J Machiels Title: Primary combined squamous and small cell carcinoma of the
larynx: report of two cases and discussion of treatment modalities Source: Oto-RhinoLaryngology, 2006; Volume 263, Number 8 / 786-790
2.3.3.14. Author(s): L Kovac, M Gjuric, S Branica, K Dawidowsky, S Seiwerth Title:
Small cell neuroendocrine carcinoma in the petrous apex Source: Journal of
Laryngology & Otology (2006), 120: 74-76
2.3.3.15. Author(s): N. Güler, P. Yumuk, D. Ilguy, V. Olgac, J. Greer Title: Limited
Painful Mouth Opening Source: Journal of Oral and Maxillofacial Surgery, Volume
63, Issue 8, Pages 1201-1205
2.3.3.16. Author(s): R. Simon, P. Bourne, Q. Yang, B. Spaulding, P. di Sant'Agnese, H.
Wang, H. Xu Title: Extrapulmonary small cell carcinomas express K homology domain
containing protein overexpressed in cancer, but carcinoid tumors do not Source: Human
Pathology, Volume 38, Issue 8, Pages 1178-1183
2.3.3.17. Author(s): WT hsueh, WC Su, FF Chen Title: Experiences of Radiotherapy on
Extrapulmonary Small Cell Carcinoma Source: 2005, 2, 24.
18
2.3.3.18. Author(s): DE Demellawy, MA Khalifa, N Ismiil, S Wong, Z Ghorab Title:
Primary colorectal small cell carcinoma: A clinicopathological and immunohistochemical
study of 10 cases Source: Diagn Pathol. 2007; 2: 35.
2.3.3.19. Author(s): Yuan ZY, Guan ZZ, Zhou ZM, Xia Y, Huang WZ, Yang XL.Title:
Extrapulmonary small cell carcinoma in 52 patients Source: Chinese Medical Journal
2006 Sep; 25(9): 1131-3.
2.3.3.20. Author(s): G. Lima, I. Varkarakis, M. Allaf, S. Fine, L. Kavoussi Title: Small cell
carcinoma of epididymis: Multimodal therapy Source: Urology, Volume 66, Issue
2, Pages 432.e19-432.e20
2.3.3.21. Author(s): AF Korcum; G Aksu; M Ozdogan; G Erdogan; O Taskin Title:
Stage I small cell carcinoma of the endometrium: survival and management options
Source: Acta Obstetricia et Gynecologica Scandinavica, 200
2.3.3.22. Author(s): EB. Rubenstein, DE Peterson, M Schubert, D Keefe, D McGuire, J
Epstein, LS. Elting, PC. Fox, C Cooksley, ST. Sonis,Title: Clinical practice guidelines for
the prevention and treatment of cancer therapy-induced oral and gastrointestinal
mucositis Source: Cancer 2004 Volume 100, Issue S9 , Pages 2026 – 2046
2.3.3.23. Author(s): PJ Hancock, JB Epstein, GR Sadler Title: Oral and dental
management related to radiation therapy for head and neck cancer Source: J Can Dent
Assoc 2003, Vol 69 No: 9, 585-590
2.3.3.24. Author(s): DB. McGuire, ME Correa, J Johnson, P Wienandts, Title: The role
of basic oral care and good clinical practice principles in the management of oral
mucositis Source: Supportive Care in Cancer 2006, Vol 14, No 6, 541-547
2.3.3.25. Palliative Medicine Handbook 3. Dr lan Back 2001
2.3.3.26. Author(s): DJ Harris, MT Knobf, Title: Assessing and Managing
Chemotherapy-Induced Mucositis Pain Source: Clinical Journal of Oncology Nursing,
2004, Vol 8, No 6, 622-628
2.3.3.27. Author(s): EMB Costa; MZ Fernandes; LB Quinderé; LB Souza; LP Pinto Title:
Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia
Source: Pesqui. Odontol. Bras. 2003;17(2):147-50
2.3.3.28. Author(s): D. Alterio, B. Jereczek-Fossa, G. Zuccotti, M. Leon, E. Omodeo
Sale, M. Pasetti, T. Modena, P. Perugini, L. Mariani, R. Orecchia Title: Tetracaine oral gel
in patients treated with radiotherapy for head-and-neck cancer: Final results of a phase II
study Source: International Journal of Radiation Oncology*Biology*Physics, Volume
64, Issue 2, Pages 392-395
2.3.3.29. Author(s): B Quinn, C.M.J. Potting, R Stone, N.M.A. Blijlevens, M Fliedner, A
Margulies, L SharpTitle: Guidelines for the assessment of oral mucositis in adult
chemotherapy, radiotherapy and haematopoietic stem cell transplant patients Source: Eur
J Cancer. 2007 doi: 10.1016 / j.ejca. 2007. 09. 014
2.3.3.30. Author(s): MC Guedes; R Weber; MVS Gomez; RB Neto; CG Peralta; RF
Bento Title: Influence of evoked compound action potential on speech perception in
cochlear implant users Source: Rev. Bras. Otorrinolaringol. vol.73 no.4 São
Paulo July/Aug. 2007
19
2.3.3.31. Author(s): AP Chaves; JAP Gomes; ALH Lima Title: Ocular changes induced
by chemotherapy Source: Arq Bras Oftalmol. 2007;70(4):718-25
2.3.3.32. Author(s): Debra J Harris Title: Cancer treatment-induced mucositis pain:
strategies for assessment and management Source: Dove Medical Press, Sepp 2006,
Vol 2, Iss 3, Page 251-258
2.3.3.33. Author(s): J. M. Blazeby , C. Metcalfe , J. Nicklin , C. P. Barham , J. Donovan,
D. Alderson Title: Association between quality of life scores and short-term outcome
after surgery for cancer of the oesophagus or gastric cardia Source: British Journal of
Surgery , 2005 Volume 92, Issue 12 , Pages 1502 – 1507
2.3.3.34. Author(s): Y. Dan, J. So, K. Yeoh Title: Endoscopic Screening for Gastric
Cancer. Source: Clinical Gastroenterology and Hepatology, Volume 4, Issue 6, Pages
709-716
2.3.3.35. Author(s): Bonnetain F, Bouche O, Conroy T, Arveux P, Raoul JL, Giovanni M,
Etienne PL, Mitry E, Seitz JF, Rougier P, Gırault C, Bedenne L, Title: Longitudinal
quality of life study in patients with metastatic gastric cancer. Source: Gastroenterol Clin
Biol 2005;29:1113-1124
2.3.3.36. Author(s): Scurtu R, Groza N, Otel O, Goia A, Funariu G Title: Quality of Life
in Patients with Esophagojejunal Anastomosis after total Gastrectomy for Cancer.
Source: Rom J Gastroenterol 2005, Vol 14. No 4, 367-372
2.3.3.37. Author(s): Sadighi S, Hohagheghi MA, Montazeri A, Sadighi Z Title: Quality of
life in patients with advanced gastric cancer: a randomizad trial comparing Docetaxel
Cisplatin 5-FU (TCF) with Epirubicin Cisplatin 5-FU (ECF). Source: BMC Cancer 2006;
1471/2407/6/274
2.3.3.38. Author(s): Olivier B Title: Comment am liorer le pronostic du cancer gastrique
en France ? Source: Gastroenterol Clin Biol 2005;29:7-10
2.3.3.39. Author(s): P. Costa, J. Carraca, A. Sofia Brito, N. Figueiredo, P. Lages Title:
Avaliação multifactorial da qualidade de vida em doentes gastrectomizados por cancro
gástrico. estudo piloto de métodos de avaliação Source: J Port Gastrenterol 2006,
13:174-180
2.3.3.40. Author(s): Satoshi M, Adrian AK, Akira T, Yasuhiro K, Takanori M, Junichi S
Title: Assessment and data analysis of health-related quality of life in clinical trials for
gastric cancer treatments Source: Gastric Cancer 2006, Vol 9, No 4, 254-261
2.3.3.41. Author(s): T Conroy, F Marchal, JM. Blazeby Title: Quality of Life in Patients
with Oesophageal and Gastric Cancer: An Overview Source: Oncology 2006;70:391-402,
2.3.3.42. Author(s): CC Huang , HH Lien , YC Sung , HT Liu , WC Chie Title: Quality of
life of patients with gastric cancer in Taiwan: validation and clinical application of the
Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-STO22 Source:
Psycho-Oncology, Volume 16, Issue 10 , Pages 945 – 949
2.3.3.43. Author(s): JM Bae, S Kim, YW Kim, KW Ryu, JH Lee, JH Noh, TS Sohn,
SK Hong, SM Park, CH You, JH Kim, MK Lee, YH Yun Title: Health-related quality of life
among disease-free stomach cancer survivors in Korea Source: Quality of Life
Research, 2006, Vol 15 No: 10 / 1587-1596
20
2.3.3.44. Author(s): P. Lagergren, P. Fayers, T. Conroy, H. Stein, O. Sezer, R.
Hardwick, E. Hammerlid, A. Bottomley, E. Van Cutsem, J. Blazeby Title: Clinical and
psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess
health-related quality of life in patients with cancer of the oesophagus, the oesophago–
gastric junction and the stomach. Source: European Journal of Cancer, Volume
43, Issue 14, Pages 2066-2073
2.3.3.45. Author(s): Y. Yun, S. Kim, K. Lee, S. Park, Y. Kim Title: Age, sex, and
comorbidities were considered in comparing reference data for health-related quality of
life in the general and cancer populations Source: Journal of Clinical
Epidemiology, Volume 60, Issue 11, Pages 1164-1175
2.3.3.46. Author(s): R Pai, C Lin, T Tran, A Tarnawski Title: Leptin activates STAT and
ERK2 pathways and induces gastric cancer cell proliferation Source: Biochemical and
Biophysical Research Communications 2005, Vol 331, Iss 4, 17, Pages 984-992
2.3.3.47. Author(s): I Wolf, S Sadetzki, H Kanety, Y Kundel, C Pariente, N Epstein, B
Oberman, R Catane, B Kaufman, I Shimon, Title: Adiponectin, ghrelin, and leptin in
cancer cachexia in breast and colon cancer patients Source: Cancer, 2006, Vol 106, Iss
4, Pages 966-973
2.3.3.48. Author(s): Dai Shida, Joji Kitayama, Ken Mori, Toshiaki Watanabe and
Hirokazu Nagawa Title: Transactivation of Epidermal Growth Factor Receptor Is Involved
in Leptin-Induced Activation of Janus-Activated Kinase 2 and Extracellular Signal–
Regulated Kinase 1/2 in Human Gastric Cancer Cells Source: Cancer Research 65,
9159-9163, October 15, 2005
2.3.3.49. Author(s): M Koda, M Sulkowska, LK Koda, E Surmacz, S Sulkowski, Title:
Overexpression of the obesity hormone leptin in human colorectal cancer Source:
Journal of Clinical Pathology 2007;60:902-906
2.3.3.50. Author(s): ER Ropelle, JR Pauli, KG Zecchin, M Ueno, CT Souza, J Morari,
MC Faria, LA Velloso, MJA Saad, JBC Carvalheire Title: A Central Role For Neuronal
Amp Actıvated Proteın Kınase (Ampk) In Cancer-Induced Anorexıa
Source:
Endocrinology 2007, Vol. 148, No. 11 5220-5229
2.3.3.51. Author(s): Douglas A Corley Title: Obesity and the rising incidence of
oesophageal and gastric adenocarcinoma Source: Gut 2007;56:1493-1494
2.3.3.52. Author(s): M Koda, M Sulkowska, L Kanczuga-Koda, S Cascio, G Colucci, A
Russo, E Surmacz, S Sulkowski Title: Expression of the obesity hormone leptin and its
receptor correlates with hypoxia-inducible factor-1 in human colorectal cancer Source:
Annals of Oncology 2007 18(Supplement 6):vi116-vi119
2.3.3.53. Author(s): Petersen SL; Wagner A; Gimsing P. Title: Cerebral and meningeal
multiple myeloma after autologous stem cell transplantation. A case report and review of
the literature. Source: AMERICAN JOURNAL OF HEMATOLOGY 1999, Vol 62, Iss 4, pp
228-233.
2.3.3.54. Author(s): Wellwood J; Taylor K; Wright S; Bentley M; Hill G; Phan H; Norris D;
Livsey R. Title: Relapsed plasma cell leukaemia presenting with aggressive
extramedullary plasmacytomas in the meninges and testis - A missed opportunity for
induction CNS prophylaxis. Source: LEUKEMIA & LYMPHOMA 2002, Vol 43, Iss 4, pp
893-896
21
2.3.3.55. Author(s): Hayes-Lattin B; Blanke CD; Deloughery TG. Title: Pulmonary and
intracerebral plasmacytomas in a patient without multiple myeloma: A case report.
Source: AMERICAN JOURNAL OF HEMATOLOGY 2003, Vol 73, Iss 2, pp 131-134
2.3.3.56. Author(s): C Pontikoglou; C Fragos; E Kolyvaki; G Samonis a; GD
Eliopoulos; HA.Papadaki. Title: Multiple myeloma involving the central nervous system: a
report of two cases with unusual manifestations Source: Leukemia and Lymphoma,
Volume 46, Issue 5 May 2005 , pages 737 – 741
2.3.3.57. Author(s): JT Rosal, I Aleman, J Ronquillo, I Puerto, L Rodriguez Title:
Glioblastoma multiforme arising in the setting of multiple myeloma Source: Haema
2005; 8(4):704-706
2.3.3.58. Author(s): Asherson RA; Cervera R. Title: Antiphospholipid antibodies and
infections. Source: ANNALS OF THE RHEUMATIC DISEASES 2003, Vol 62, Iss 5, pp
388-393
2.3.3.59. Author(s): Cervera R; Asherson RA; Acevedo ML; Gomez-Puerta JA; Espinosa
G; de la Red G; Gil V; Ramos-Casals M; Garcia-Carrasco M; Ingelmo M; Font J. Title:
Antiphospholipid syndrome associated with infections: clinical and microbiological
characteristics of 100 patients. Source: ANNALS OF THE RHEUMATIC DISEASES
2004, Vol 63, Iss 10, pp 1312-1317.
2.3.3.60. Author(s): Ramos-Casals M; Cervera R; Lagrutta M; Medina F; GarciaCarrasco M; de la Red G; Bove A; Ingelmo M; Font J. Title: Clinical features related to
antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV
infection): Description of 82 cases. Source: CLINICAL INFECTIOUS DISEASES 2004,
Vol 38, Iss 7, pp 1009-1016
2.3.3.61. Author(s): Asherson RA; Shoenfeld Y. Title: Human immunodeficiency virus
infection, antiphospholipid antibodies, and the antiphospholipid syndrome. Source:
JOURNAL OF RHEUMATOLOGY 2003, Vol 30, Iss 2, pp 214-219
2.3.3.62. Author(s): P Hopwood Title: Psychosocial aspects of risk communication and
mutation testing in familial breast-ovarian cancer Source: Current Opinion in Oncology.
July 2005, 17(4):340-344,
2.3.3.63. Author(s): A MacArthur, CD Bajdik, JJ Spinelli, C Kim-Sing, RP Gallagher
Title: Predicting interest in genetic counseling and testing for cancer susceptibility: The
British Columbia Family Cancer Survey Pilot Study Source: BC Medical Journal
Volume 48, Number 5, June 2006, page 222-225
2.3.3.64. Author(s): U. Gallkowski, H Muller, S. Manekeller, J. Boese-Landgraf, S.
Ridwelski Title: Umgang und Pflege implantierter Portkathetern bei Tumorpatiaenten –
ein interdisziplinres Problem Source: Surgical Oncology
2.3.3.65. Author(s): ÖU Yesilbalkan Title: Onkoloji Hastalarında Sık Kullanılan Venöz
Giriş Aracı: İmplante Port Kateter Source: C.Ü. Hemşirelik Yüksek Okulu Dergisi 2005, 9
(2)
2.3.3.66. Author(s): KW Jauch, W Schregel, Z Stanga Title: 9 Technik und Probleme
der Zugange in der parenteralen Ernahrung Source: Aktuel Ernaehr Med 2007; 32,
Supplement 1: S41-S53
2.3.3.67. Author(s): N. Villanueva; E. Esteban; I. Muñiz J. VieitezI L. Olay; I. Jimenez; P.
Jimenez; M. Luque; B. Llorente; M. Capelan; E. Estrada; Y. Fernández; J. Fra; A. J.
Lacave Title: Radioterapia torácica con 70 Gy concurrente con docetaxel o paclitaxel
22
semanal tras quimioterapia de inducción en pacientes con carcinoma de pulmón no
microcítico localmente avanzado. Estudio prospectivo de tolerancia y eficacia Source:
Oncología (Barc.) v.29 n.10 Madrid dic. 2006
2.3.3.68. Author(s): EE Vokes, J. E. Herndon, M. J. Kelley, D. Watson, M. G. Cicchetti,
M. R. Gren Title: Induction chemotherapy followed by concomitant chemoradiotherapy
(CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung
cancer (NSCLC): Initial analysis of a randomized phase III trial Source: Journal of
Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol
22, No 14S (July 15 Supplement), 2004: 7005
2.3.3.69. Author(s): YS Gouda, HM Kohail, NA Elddeb, AM Omar, MM El-Geneidy, YM
Elkerm
Title: Randomized Study of Concurrent Carboplatin, Paclitaxel, and
Radiotherapy Induction Chemotherapy in Patients with Locally Advanced Non Small cell
lung cancer Source: Journal of the Egyptian Nat. Cancer Inst. March 2006, Vol 18, No 1,
73-81
2.3.3.70. Author(s): Rossi P; Di Lorenzo G; Formisano R; Buzzi MG. Title:
Subcutaneous sumatriptan induces changes in frequency pattern in cluster headache
patients. Source: HEADACHE 2004, Vol 44, Iss 7, pp 713-718
2.3.3.71. Author(s): K. Paemeleire, A. Bahra, S. Evers, MS Matharu, PJ Goadsby, Title:
Medication-overuse headache in patients with cluster headache Source: NEUROLOGY
2006;67:109-113
2.3.3.72. Author(s): S Sitalakshmi, R Karuna, D Prema Title: Do plasma D-dimer levels
correlate with disease stage in colonic carcinoma? Source: Indian Journal of Surgery,
2006, Vol 68, Iss 6, Page 306-309
2.3.3.73. Author(s): JIN Xiao-shi Title: The research on the changes of the D-dimer and
fibrinogen concentrations in the patients with colorectal carcinoma Source: Journal of
Tianjin Medical University 2006, VoI．12．No．3 Sep．404-405
2.3.3.74. Author(s): E Renoult, C Buteau, V Lamarre, N Turgeon, B Tapiero Title:
Infectious risk in pediatric organ transplant recipients: Is it increased with the new
immunosuppressive agents? Source: Pediatric Transplantation 2005, 9 (4), 470–479
2.3.3.75. Author(s): Wang HX, Jı SQ, Zhu L, Lıu J, Xue M, Dıng L, Duan LN, Yan HM,
Chen HR Title: Neurological Complications Following Haploidentical Bone Marrow
Transplantation Source: Journal of Experimental Hematology 2005, Vol 13, No 6, 11281130
2.3.3.76. Author(s): Atesci FC; Baltalarli B; Oguzhanoglu NK; Karadag F; Ozdel O;
Karagoz N. Title: Psychiatric morbidity among cancer patients and awareness of illness.
Source: SUPPORTIVE CARE IN CANCER 2004, Vol 12, Iss 3, pp 161-167
2.3.3.77. Author(s): Mehta VK, Poen J, Ford J, Oberhelman H, Vierra MA, Bastidas AJ,
Fisher GA. Title: Protracted Venous Infusion 5-Fluorouracil With Concomitant
Radiotherapy Compared With Bolus 5-Fluorouracil for Unresectable Pancreatic Cancer
Source: American Journal of Clinical Oncology. 2001, 24(2):155-159,
2.3.3.78. Author(s): R Wilkowski, M Wolf, V Heinemann Title: Primary Advanced
Unresectable Pancreatic Cancer Source: Pancreatic Cancer, 2007, Vol 177, Iss 80-15,
Pages 79-93
23
2.3.3.79. Author(s): S Höcht, T Wiegel, A Siegmann, W Hinkelbein Title:
Radiochemotherapy in Unresectable Pancreatic Cancer
Source: Front Radiat Ther
Oncol. 2004, Vol 38, pp 87-93.
2.3.3.80. Author(s): GJ Chang, MAR Bigas, JM Skibber, VA Moyer Title: Lymph Node
Evaluation and Survival After Curative Resection of Colon Cancer: Systematic Review
Source: Journal of the National Cancer Institute 2007 99(6):433-441
2.33.81. Author(s): P Greco, S Andreola, G Magro, F Belli, G Giannone, GF Gallino,
E Leo Title: Potential pathological understaging of pT3 rectal cancer with less than 26
lymph nodes recovered: a prospective study based on a resampling of 50 rectal
specimens Source: Virchows Archiv, 2006, Vol 449, No 6, Page 647-651
2.3.3.82. Author(s): Caronna R; Cardi M; Sammartino P; Mangioni S; Pittau G;
Scozzafava S; Catinelli S; Chirletti P; Stipa V. Title: Functional results of a personal
technique of reconstruction after pancreaticoduodenectomy. Source: JOURNAL OF
EXPERIMENTAL & CLINICAL CANCER RESEARCH 2003, Vol 22, Iss 4, pp 187-189
2.3.3.83. Author(s): JK Aronson Title: A worldwide yearly survey of new data and trends
Source: Elsevier, Side Effects of Drugs Annual 26,
2.3.3.84. Author(s): J Shuster Title: ISMP Adverse Drug Reactions Reports Source:
Hospital Pharmacy, 2002, Volume 37, Number 3, pp 242–249, 333
2.3.3.85. Author(s): LCS Martinez, NEC Ceballos, EM Carrillo Title: To know the
survival in patients with renal cell carcinoma Source: Collegio Mexicano de Urologia,
2002, Vol 17, No 4, pp 187-192
2.3.3.86. Author(s): DE Rapp, WS Reynolds, A Lucioni, GT Bales Title: Surgical
technique using AdVance™ Sling placement in the treatment of post-prostatectomy
urinary Incontinence Source: International Braz J Urol. 2007, Vol. 33 (2): 231-237,
2.3.3.87. Author(s): G Barbagli, M Lazeri Title: Surgical technique using AdVance™
Sling placement in the treatment of post-prostatectomy urinary Incontinence Source:
International Braz J Urol. 2007, Vol. 33 (4): 461-469
2.3.3.88. Author(s): S Suryanarayanan Title: Desıgn, development, and
characterızatıon of a prototype dıgıtal mammography system Source: Georgia Institute
of Technology, 2006
2.3.3.89. Author(s): Garsten J. Title: The Yale-Affiliated gastroenterology program Personal note. Source: JOURNAL OF CLINICAL GASTROENTEROLOGY 1996, Vol 22,
Iss 4, pp 255-260.
2.3.3.90. Author(s): Lier H; Thees C; Nadstawek J. Title: Anaesthesia and epilepsy - a
review. Source: ANASTHESIOLOGIE & INTENSIV MEDIZIN 2003, Vol 44, Iss 12, pp
857-868
2.3.3.91. Author(s): Lorenzo OA; Fernandez-Monras F; Arago JV; Abaurrea FR. Title:
Progressive systemic sclerosis and inflammatory bowel disease. Source: REVISTA
ESPANOLA DE ENFERMEDADES DIGESTIVAS 2002, Vol 94, Iss 6, pp 372-373.
2.3.3.92. Author(s): Epstein JB; Truelove EL; Oien H; Allison C; Le ND; Epstein MS.
Title: Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to
cancer or cancer therapy. Source: ORAL ONCOLOGY 2001, Vol 37, Iss 8, pp 632-637.
24
2.3.3.93. Author(s): Moncoucy X; Hamon R; Diebold MD; Coussinet S; Pennaforte JL;
Thiefin G; Cadiot G. Title: Systemic sclerosis and ulcerative colitis. Source:
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 2001, Vol 25, Iss 3, pp 324-325
2.3.3.94. Author(s) Ulusakarya A; Youssef A; Bayle C; Vantelon JM; Munck JN. Title:
Plasma cell meningitis after an autograft in a patient with multiple myeloma. Source:
LEUKEMIA & LYMPHOMA 1999, Vol 34, Iss 5-6, pp 633-634
2.3.3.95. Author(s): Leleu X; Jouet JP; Plantier I; Zandecki M; Lai JL; Mucha D; Lejeune
JP; Bauters F; Facon T. Title: Isolated neurological relapse following stem cell
transplantation in plasma cell leukemia: a report of two cases. Source: LEUKEMIA 1999,
Vol 13, Iss 2, pp 307-309.
2.3.3.96. Mohammadine E; Benabdellah W; Lahlou MK; Benamr S; Essadel H; Belmahi
AM; Abbassi A; Ukkas A; Taghy A; Chad B; Zizi A; Belmahi A. Title: About a pseudo
neoplasic colic stenosis preceding systemic scleroderma. Source: ANNALES DE
GASTROENTEROLOGIE ET D HEPATOLOGIE 1997, Vol 33, Iss 3, pp 127-131.
2.3.3.97. Author(s): Heymann WR. Title: Advances in the cutaneous manifestations of
thyroid disease. Source: INTERNATIONAL JOURNAL OF DERMATOLOGY 1997, Vol
36, Iss 9, pp 641-645
2.3.3.98. Author(s): Kilchenstein W; Muller OA. Title: Progressive systemic scleroderma
- Involvement of the gastrointestinal tract. Source: AKTUELLE RHEUMATOLOGIE 1996,
Vol 21, Iss 4, pp 184-189
2.3.3.99. Author(s): HEYMANN WR. Title: CUTANEOUS MANIFESTATIONS OF
THYROID-DISEASE. Source: JOURNAL OF THE AMERICAN ACADEMY OF
DERMATOLOGY 1992, Vol 26, Iss 6, pp 885-902.
2.3.3.100. Author(s): Rohwer, N. ve ark. “HIF-1alpha determines the metastatic
potential of gastric cancer cells,” Br J Cancer., 100(5):772-81 (2009).
2.3.3.101. Author(s): Casado, E. ve ark. “UFT (tegafur-uracil) in rectal cancer,” Ann
Oncol., 19(8):1371-8, Review, (2008).
2.3.3.102. Author(s): 1. Akil, N. ve ark., “High-risk human papillomavirus infections in
breast cancer in Syrian women and their association with Id-1 expression: a tissue
microarray study,” Br J Cancer, 5;99(3):404-7 (2008)
2.3.3.103. Author(s): Liang, W. Ve ark., “Hypothetic association between human
papillomavirus infection and breast carcinoma,” Med Hypotheses., 70(2):305-7 (2008).
2.3.3.104 Author(s): Cazzaniga, M. ve ark., “Analysis of the presence of cutaneous and
mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its
role in breast carcinogenesis,” Breast Cancer Res Treat., 114(3):599-605 (2009).
2.3.3.105. Author(s):
Mendizabal-Ruiz, A.P. ve ark., “Low frequency of human
papillomavirus DNA in breast cancer tissue,” Breast Cancer Res Treat., 114(1):189-94
(2009).
2.3.3.106. Author(s): Amarante, M.K. ve ark., “The possible involvement of virus in
breast cancer,” J Cancer Res Clin Oncol., 135(3):329-37 (2009).
2.3.3.107. Author(s): Sun, L. Ve ark., “In GFP with high risk HPV-18E6 fusion protein
expressed 293T and MCF-7 cells, the endogenous wild-type p53 could be transiently
phosphorylated at multiple sites,” J Exp Clin Cancer Res., 27:35 (2008).
25
2.3.3.108. Author(s): He, Q. Ve ark., “The correlations between HPV16 infection and
expressions of c-erbB-2 and bcl-2 in breast carcinoma,” Mol Biol Rep., 36(4): 807-12 (2009).
2.3.3.109. Author(s): Koppie, T.M. ve ark., “Standardization of pelvic lymphadenectomy
performed at radical cystectomy: can we establish a minimum number of lymph nodes that
should be removed?,” Cancer., 107(10):2368-74 (2006).
2.3.3.110. Author(s): Govindarajan, A. ve ark., “Lymph node evaluation in early-stage colon
cancer,”
Clin Colorectal Cancer., 7(4):240-6 (2008).
2.3.3.111. Author(s): York Health Economics c o n s o r t ı u m, Department Of Health,
Bowel Cancer Services: Costs and Benefits Literature Review, York Health, April 2007
2.3.3.112. Author(s): Tzanopoulou, S. ve ark. “Synthesis, characterization, and biological
evaluation of M(I)(CO)(3)(NNO) complexes (M = Re, Tc-99m) conjugated to 2-(4aminophenyl) benzothiazole as potential breast cancer radiopharmaceuticals”, Journal Of
Medicinal Chemistry, 49, 5408-5410 (2006).
2.3.3.113. Author(s): Richardson, G. ve ark. “Chemotherapy induced diarrhea,” J Oncol
Pharm Pract., 13(4):181-98. Review (2007).
26
2.4. Diğer kongre sempozyum bildirileri:
2.4.1. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings)
basılan bildiriler :
Uluslararası kongre / sempozyumlarda sunulan diğer bildiriler:
2.4.1.1. Vassallo P, Pearson WN, Turhal N. The diagnostic role of transesophageal echo
(TEE) in patients with pulmonary emboli but no obvious embolic source. Chest, 1993,
104:2, 141S.
2.4.1.2. Terk M, Turhal N, Mandeli J, et al: Long-term follow-up of combined modality
therapy for unresectable pancreatic cancer. Proceedings of American Society of Clinical
Oncology 1996, 16, 307a.
Atıflar: 3 Adet
2.4.1.3. Turhal NS, Bruckner HW. Neoadjuvant treatment of gastric and
gastroesophageal cancers. Journal of Balkan Union of Oncology 1998, 3:49.
2.4.1.4. Turhal NS, Isola L, Scigliano E, Vlachos A, Fruchtman S. A study of cyclosporine
A and imipenem associated grand mal seizures in allogeneic bone marrow
transplantation (BMT). Annals of Oncology 1998 9:140.
Atıflar: 2 Adet
2.4.1.5. Erdal S, Karacay S, Turhal NS. Symptomatic Treatment of Chemotherapy
Induced Mucositis. Anti-Cancer Treatment 1999 9:259.
2.4.1.6. Turhal NS, Ekenel M, Ozgan A, Bekiroglu N. Attitude Toward Genetic Testing for
Cancer Risk Assessment in Turkish Society. European Journal of Gynecological
Oncology 1999 20(Supp): 121-122.
2.4.1.7. Turhal NS, Kabakas F, Atalay G, Karamanoglu A. Outpatient Cancer Care in a
Turkish University Hospital. Proceedings of American Society of Clinical Oncology 1999,
1652.
2.4.1.8. Salepci T, Turhal NS. Cisplatin and etoposide in extra pulmonary small cell
cancer. Proceedings of American Society of Clinical Oncology 2043, 2000.
2.4.1.9. Turhal NS, Gurses I, Akbaba P. Neoplastic disease prevalence during 1998-99
in Marmara University hospital in Istanbul Turkey. Proceedings of American Society of
Clinical Oncology 1773, 2000
2.4.1.10. Guler N, Yucel I, Ozet A, Bilkay BC, Erkisi M, Onur H, Buyukunal E, Turhal S,
Firat D. Vinorelbine, Epirubicin and 5 FU combination in the first line treatment of
metastatic breast carcinoma. Annals of Oncology 2000 11(4): 137.
27
2.4.1.11. Abacıoglu U, Sengoz M, Atasoy B, Turhal S. A pilot study of low dose weekly
gemcitabine and concurrent radiation in patients with locally advanced pancreatic cancer.
The third annual global oncology young investigators´ meeting. 2001.
2.4.1.12. Sengoz M, Caglar H, Abacıoglu U, Atasoy B, Turhal S, Gulluoglu B. Patient
characteristics and treatment results of postoperatively irradiated breast cancer patients.
The Breast Journal 2001 7(5): 42.
2.4.1.13. Atalay G, Gumus M, Aliustaoglu M, Turhal NS. The method of detection and its
relationship with the disease stage in Turkish breast cancer patients. The Breast Journal
2001 7(5): 47
2.4.1.14. Dincbas FO, Koca S, Altınel A, Hancılar T, Cavusoglu M, Turhal S, Uskent N,
Ozguroglu M, Okkan S. Continuous accelerated hyperfractionated radiotherapy (CHART)
plus chemotherapy (CT) with vinorelbine (VB) and cisplatinum (CDDP) in locally
advanced NSCLC (TOG-011 study). European Journal of Cancer 2001 37(6): S53
2.4.1.15. Gumus M, Atalay G, Aliustaoglu M, Guler S, Ekenel M, Karamanoglu A, Turhal
NS. Attitude toward genetic testing in Turkish society. European Journal of Cancer 2001
37(6): S237.
2.4.1.16. Gumus M, Atalay G, Aliustaoglu M, Karamanoglu A, Turhal NS. Outcome of
patients after adjuvant treatment in stage B2/C colon cancer in Istanbul. Twelfth
International Congress on Anti-Cancer Treatment. Proceeding Book, February 2002: 150.
2.4.1.17. Aliustaoglu M, Gumus M, Atalay G, Sengoz M, Abacıoğlu U, Karamanoglu A,
Turhal NS. The survival characteristics of the stage IIIB and IV non small cell lung cancer
patients in Marmara University Hospital in Istanbul, Turkey. Twelfth International
Congress on Anti-Cancer Treatment. Proceeding Book, February 2002: 124.
2.4.1.18. Atalay G, Gumus M, Aliustaoglu M, Turhal NS. Predictive factors associated
with axillary lymph node metastasis (ALNM) in T1, T2 and T3 breast carcinomas.
European Journal of Cancer 2002 38(3): S115.
2.4.1.19. Karamanoglu A, Yumuk PF, Gumus M, Aliustaoglu M, Selimen D, Sengoz M,
Turhal NS. Port needles need not be removed as frequently in infusional cancer
chemotherapy, our experience in a university hospital in Istanbul, Turkey. Bone Marrow
Transplantation 2002 29(2): S275.
2.4.1.20. Gumus M, Aliustaoglu M, Atalay G, Dane F, Caglar H, Sengoz M, Turhal NS.
The extension of nodal sampling in colorectal cancer patients in Marmara University
Hospital, Istanbul. Proceedings of ASCO Volume 21, 2002: 133b.
2.4.1.21. Turhal NS, Efe B, Gumus M, Aliustaoglu M, Karamanoglu A, Sengoz M. Patient
satisfaction in Marmara University outpatient chemotherapy unit in Istanbul. Proceedings
of ASCO Volume 21, 2002: 252b.
Atıflar: 1 Adet
2.4.1.22. Aliustaoglu M, Atalay G, Gumus M, Turhal NS. Outcome of adjuvant treatment
in elderly Turkish breast cancer patients. Proceedings of ASCO Volume 21, 2002: 259b.
2.4.1.23. Dane F, Turhal NS, Gumus M, Dede F, Cakaloglu F, Savci D, Gulluoglu B,
Kayahan M, Turoglu T. 99m-Tc-MDP scintimammography to assess angiogenesis in
patients with untreated breast cancer. Proceedings of ASCO Volume 21, 2002: 291b.
28
2.4.1.24. Aliustaoglu M, Yumuk F, Gumus M, Ekenel M, Bolukbas F, Bolukbas C, Atalay
G, Mutlu N, Turhal NS. Plasma D-dimer levels in patients with benign and malignant
gastric lesions. Annals of Oncology 2002 Vol 13 (Supp 5): 190.
2.4.1.25. Atalay G, Gumus M, Aliustaoglu M, Abacıoglu U, Sengoz M, Gulluoglu B,
Turhal NS. Outcome of Turkish breast cancer patients who received epirubicin based
adjuvant chemotherapy. Annals of Oncology 2002 Vol 13 (Supp 5):44.
2.4.1.26. Ekenel M, Atalay G, Gumus M, Yumuk F, Aliustaoglu M, Karamanoglu A,
Turhal NS. Incidence of chemotherapy induced amenorrhea in premenopausal Turkish
breast cancer patients. Fourteenth International Congress on Anti-Cancer Treatment
Proceeding Book, February 2003: 159.
2.4.1.27. Ekenel M, Atalay G, Gumus M, Yumuk F, Aliustaoglu M, Karamanoglu A,
Turhal NS. Outcome of breast cancer patients after adjuvant therapy in Istanbul, Turkey.
Fourteenth International Congress on Anti-Cancer Treatment Proceeding Book,
February 2003: 160
2.4.1.28. Aydin SZ, Yumuk PF, Ekenel M, Gumus M, Aliustaoglu M, Karamanoglu A,
Sengoz M, Turhal NS. The absence of irinotecan associated acute diarrhea with atropine
premedication. Proceeding Book, 205-206, 14th International Congress on Anti-Cancer
Treatment, Paris, France, 1-4 February, 2003.
2.4.1.29. Turhal NS, Gumus M, Ekenel M, Guzet E, Yumuk F, Avery B. Prognostic
factors and treatment outcomes of adjuvant breast cancer patients in two locations:
Tennessee USA and Istanbul Turkey. Proceedings of ASCO Volume 22, 2003: 556.
2.4.1.30. Komurcu S, Turhal NS, Altundag K, Atahan L, Savas-Turna H, Manavoglu O,
Yavuz AA, Ozkok S, Aliustaoglu M, Altınbas M, Pak Y, Cooper R, Yaylacı M, Demirkan
B, Engin K, Ozdemir F. A clinical evaluation of transdermal fentanyl in adults with cancer
pain: Phase IV, multicentre trial. Supportive Care in Cancer 2003 11(6): A39.
2.4.1.31. Aliustaoglu M, Gumus M, Yumuk F, Ekenel M, Karamanoglu A, Sengoz M,
Turhal NS. The survival characteristics of the stage IIIB and IV non small cell lung
cancer patients in Marmara University hospital in Istanbul, Turkey. Lung cancer 2003 Vol
41 Supp:2 S94.
2.4.1.32. Dane F, Iyikesici S, Gumus M, Yumuk PF, Ekenel M, Atalay G, Karamanoglu A,
Turhal NS. Adjuvant treatment outcome of high risk stage II and III colon cancer patients
treated in Marmara University, Istanbul. Proceeding Book, 206-207, 15th International
Congress on Anti-Cancer Treatment, Paris, France, 9-12 February, 2004 p247.
2.4.1.33. Gunduz F, Yumuk PF, Dane F, Peker O, Ekenel M, Iyikesici S, Atalay G, Turhal
NS. Mantle cell lymphoma presenting as a breast mass. Proceeding Book, 206-207, 15th
International Congress on Anti-Cancer Treatment, Paris, France, 9-12 February, 2004
p211.
2.4.1.34. Dane F, Yumuk PF, Turhal NS, Ekenel M, Basaran G, İyikesici S, Tecimer C.
Folfox4 in metastatic colorectal cancer (MRC) patients who progressed after infusional
5FU/Irinotecan based combination regimens. Proceedings ASCO Volume 23, 2004:3729.
2.4.1.35. Aliustaoğlu M, Gumus M, Midi A, Celikel C. A, Ekenel M, Yumuk PF, Basaran
G, Turhal NS. Prognostic value of thymidylate synthase and cox-2 expression in
colorectal cancer patients tumors. Proceedings ASCO Volume 23, 2004:3731
29
2.4.1.36. Cabuk D, Yumuk PF, Abacioglu U, Demir G, Dane F, Gumus M, Ozguroglu M,
Ekenel M, Basaran G, Turhal NS. Is the incidence of anal cancers different in Moslem
societies. Proceedings ASCO Volume 23, 2004:4233
2.4.1.37. Abacioglu U, Yumuk PF, Caglar H, Sengoz M, Turhal NS. Results of
concurrent chemoradiotherapy (CRT) with low dose weekly gemcitebine (G) in stage III
non-small cell lung lung cancer (NSCLC). Proceedings ASCO Volume 23, 2004:7318
2.4.1.38. Yumuk PF, Turhal NS, Gumus M, Hatabay NF, Turken O, Ozkan A, T. Selepci,
Aliustaoglu M, Ekenel M, Ahiskali R. Paclitaxel (P) (day 1 and 8) and carboplatin (C)
given on every 3 weeks in advanced (stage III-IV) non-small cell lung cancer (NSCLC).
Proceedings ASCO Volume 23, 2004:7321
2.4.1.39. Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Ekenel M, Basaran G, Dane F,
Kaya H, Barisik N, Turhal NS; Human papilloma virus: Is it a new etiological factor in
breast cancer?. Proceedings ASCO Volume 23, 2004:9635
2.4.1.40. Turhal NS, Popov I. Colorectal cancer care in Balkans. Procedings of Balkan
Union of Oncology Educational Book 2004 C-109
2.4.1.41. Basaran GA, Ekenel M, Demirkalem P, Cakır T, Gulluoglu B, Gumus M, Dane
F, İyikesici S, Yumuk F, Turhal S. Clinical outcome of breast cancer patients with
pT1N0M0 disease. Annals of Oncology 2004 15(3):257P, iii68.
2.4.1.42. Dane F, Turhal NS, İyikesici S, Gumus M, Yumuk PF, Basaran G, Ekenel M,
Avery B. Clinical features and adjuvant treatment outcomes of colon cancer in two
outpatient populations of Knoxville Tennessee and İstanbul Turkey. Annals of Oncology
2004 15(3): 355P, iii95
2.4.1.43. Iyikesici S, Turhal NS, Yumuk PF, Dane F, Gumus M, Basaran G, Ekenel M,
Avery B. Treatment outcomes in non-small cell lung cancer patients: Comparison
between Marmara University, İstanbul Turkey and Knoxville Tennessee. Annals of
Oncology 2004 15(3): 741, iii195.
2.4.1.44. İyikesici MS, Kefeli U, Basaran G, Dane F, Ekenel M, Yumuk PF, Turhal NS,
The prognostic impact of body mass index (BMI) in early breast cancer (BC) patient (pts)
2.4.1.45. Yumuk PF, Yumuk VD, Yazici D, Ege B, Bekiroglu N, Dane F, Iyikesici S,
Basaran G, NS Turhal, “The impact of body mass index on cancer: A Hospital-based
study,” 14th European Congress on obesity, Blackwell Publishing, Volume 6, Supplement
1, Page 82 (Abstract 256), Athens, 2005.
2.4.1.46. Basaran G, Dane F, Iyikesici S, Ekenel M, Yumuk PF, Turhal NS, Clinical and
pathological characteristics of early breast cancer (EBC) patients <35 years old.
2.4.1.49. Ekenel M, Basaran G, Dane F, Iyikesici S, Yumuk PF, Turhal NS, Outcome of
adjuvant treatment in elderly Turkish breast cancer patients. Proceedings ASCO Volume
23, 2005:896
2.4.1.47. Cabuk D, Basaran G, Yumuk PF, Celikel C, Dane F, İyikesici MS, Ekenel M,
Turhal NS, VEGF, HIF-1 alpha and CD34 expressions in gastric tumors (tms):
Relationship with pathological factors and prognostic impact on survival. Proceedings
ASCO Volume 23, 2005:4040
30
2.4.1.48. Gumus M, Palak B, İyikesici S, Yumuk PF, Seker M, Topal A, Dane F, Salepci
T, Yayla A, Turhal NS, Outcome of elderly patients with advanced non-small cell lung
cancer. Proceedings ASCO Volume 23, 2005:7345
2.4.1.49. Yumuk PF, Turhal NS, Ahiskali R, Gumus M, Hatabay N, Turken O, Ozkan A,
Salepci T, Aliustaoglu M. P53 or Her2/neu as prognostic factors in advanced non-smallcell lung cancer treated with paclitaxel. 11th World Conference on Lung Cancer,
Barcelona, Spain. 3-6 July 2005.
2.4.1.50. Iyikesici MS, Yumuk PF, Dane F, Ekenel M, Basaran G, Turhal NS, Outcome of
patients with stage III and IV non-small cell lung cancer in Marmara University Hospital.
11th World Conference on Lung Cancer, Elsevier, Volume 49 Supp 2, S249, Barcelona,
Spain. 3-6 July 2005.
2.4.1.51. İyikesici M, Yumuk PF, Dane F, Ekenel M, Basaran G, Turhal NS, Outcome of
patients with stage III and IV non-small cell lung cancer in Marmara University Hospital,
Istanbul, Turkey. Abstract of the 11 th World Conference on Lung Cancer, Elsevier
Volume 49 Supp 2, 2005: S249
2.4.1.52. Atasoy BM, Abacioglu U, Ozgen Z, Dane F, Yumuk PF, Akgun Z, Ozden S,
Mayadagli A, Turhal NS, Sengoz M. Tolerability assessment of urasil-tegafur
(UFT)/folinic acid (FA) as concurrent chemoradiation (CRT) in adjuvant rectal cancer
treatment. Marmara University School of Medicine, Istanbul, Turkey; Lutfi Kirdar Kartal
State Hospital, Istanbul, Turkey. Proceedings ASCO Volume 24 2006:13559
2.4.1.53. Dane F, Gumus M, Iyikesici MS, Yumuk PF, Basaran G, Atasoy BM, Abacioglu
U, Cabuk D, Teomete M, Turhal NS, Outcome of rectal carcinoma patients receiving
adjuvant chemoradiotherapy in Marmara University Hospital, Istanbul, Turkey.
Proceedings ASCO Volume 24 2006:13584
2.4.1.54. Yalcin B, Aydin F, Zengin N, Ilhan M, Isikdogan A, Aykan F, Demir G, Celik I,
Turhal NS, Icli F, Akbulut H. The clinicopathological and socioeconomic features of
patients with gastric cancer in Turkey (Turkish Oncology Group) Ankara University
School of Medicine, Ankara Turkey; Karadeniz Teknik University School of Medicine,
Trabzon, Turkey; Ankara Numune Hospital, Ankara, Turkey; Yuzuncu Yil University
School of Medicine, Van, Turkey; Dicle University School of Medicine, Diyarbakir, Turkey;
Istanbul University, Oncology Institute, Istanbul, Turkey; Istanbul University, Cerrahpasa
School of Medicine, Istanbul, Turkey; Hacettepe University Oncology Hospital, Ankara
Turkey; Marmara University School of Medicine, Istanbul, Turkey. Proceedings ASCO
Volume 24 2006: 20098
2.4.1.55. Kefeli U, Karamanoglu A, Dane F, Yumuk PF, Iyikesici MS, Basaran G, Turhal
NS. Prolonged interval in Prophylactic Heparin Flushing for Maintenance Subcutaneous
Implanted Port Care in Patients with Cancer. 17th International Congress on Anti-Cancer
Treatment, Abstract Book Page 348, 30th January-2nd February 2006, Paris, France
2.4.1.56. Atasoy BM, Abacioglu U, Ozgen Z, Dane F, Yumuk FP, Akgun Z, Ozden S,
Mayadagli A, Turhal NS, M Sengoz, “Concurrent administration of urasil-tegafur and
folinic acid with radiation for locally advanced rectum cancer: tolerability and quality of life
assessments,” 25th ESTRO Annual Meeting, Leipzig, Radiother Oncol., Vol. 81 (Suppl.
1), S234, Elsevier, Ireland, 2006.
2.4.1.57. Atasoy BM, Abacioglu U, Ozgen Z, Dane F, Yumuk PF, Akgun Z, Ozden S,
Mayadagli A, Turhal NS, Sengoz M. Concomitant administration of uracil-tegafur (UFT)
and folinic acid (FA) during inradiation for locally advanced rectal cancer: tolerability
31
assessment. 6th Congress Balkan Union of Oncology, 13-16 September 2006, Sofia,
Bulgaria, 58:OP80,
2.4.1.58. Dane F, Gumus M, Iyikesici S, Basaran G, Ozturk A, Atasoy BM, Abacioglu U,
Cabuk D, Teomete M, Turhal NS, Division of Medical Oncology, Marmara University
Hospital, Istanbul, Turkey. Outcome of rectal carcinoma patients receiving adjuvant
chemoradiotherapy. 6th Congress Balkan Union of Oncology, 13-16 September 2006,
Sofia, Bulgaria, 61:PP93.
2.4.1.59. Dane F, Yumuk PF, Gumus M, Iyikesici S, Tufan A, Basaran G, Cabuk D,
Ozturk A, Erdem R, Teomete M, Turhal NS, Dept. Of Internal Medicine Division of
Oncology, Marmara University Hospital, Istanbul, Turkey. Outcome of unresectable
locally advanced and/or metastatic colorectal cancer patients receiving systemic
chemotherapy. 6th Congress Balkan Union of Oncology, 13-16 September 2006, Sofia,
Bulgaria, 64:PP107.
2.4.1.60. Turhal NS, Dept. Of Internal Medicine Division of Oncology, Marmara
University Hospital, Istanbul, Turkey. Integration of Balkan Oncology in International
Study Groups: the University of Marmara Experience. 6th Congress Balkan Union of
Oncology, 13-16 September 2006, Sofia, Bulgaria, 109:OP251.
2.4.1.61. Cabuk D, Basaran G, Iyikesici S, Ekenel M, Dane F, Teomete M, Gumus M,
Aliustaoglu M, Yumuk PF, Turhal NS, Marmara University Hospital, Medical Oncology,
Istanbul, Turkey. Outcome of adjuvant treatment in Turkish Breast Cancer (BC) patients
(PTS): single institution experience. Annals of Oncology Abstract Book of the 31st ESMO
Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/302
2.4.1.62. Yumuk PF, Gumus M, Kaya H, Alam K, Dane F, Gulluoglu B, Salepci T, Barisik
N, Basaran G, Turhal NS. Association Between Presence of HPV DNA and P53 in
Breast Cancer Patients. Annals of Oncology Abstract Book of the 31st ESMO Congress
29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/311
2.4.1.63. Basaran G, Cabuk D, Caglar H, Iyikesici S, Tebessum C, Gulluoglu B, Kaya H,
Dane F, Yumuk PF, Turhal NS. Stage I (T1N0M0) Breast Cancer (BC): Pathological
Characteristics and Clinical Outcome. Annals of Oncology Abstract Book of the 31st
ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp,
9/321
2.4.1.64. Dane F, Yumuk PF, Gumus M, Iyikesici S, Tufan A, Basaran G, Cabuk D,
Teomete M, Turhal NS, Marmara University Hospital Department of Oncology Istanbul,
Turkey. Outcome of metastatic colorectal cancer patients receiving palliative
chemotherapy in Marmara University Hospital. Annals of Oncology Abstract Book of the
31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17,
Supp, 9/378
2.4.1.65. Dane F, Gumus M, Yumuk PF, Iyikesici S, Ozturk A, Basaran G, Caglar H,
Cabuk D, Teomete M, Turhal NS, Marmara University Hospital Department of Oncology
Istanbul, Turkey. Outcome of colon cancer patients receiving adjuvant chemotherapy in
Marmara University Hospital. Annals of Oncology Abstract Book of the 31st ESMO
Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/384.
2.4.1.66. Atasoy B, Abacioglu U, Ozgen Z, Dane F, Yumuk PF, Akgun Z, Ozden S,
Mayadagli A, Turhal NS, Sengoz M. Adjuvant comcomittant administration of UrasilTegafur (UFT) and folinic acid (FA) during irradiation for locally advanced rectum cancer:
Tolerability assessment. Annals of Oncology Abstract Book of the 31st ESMO Congress
29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/401
32
2.4.1.67. Teomete M, Yumuk PF, Iyikesici S, Dane F, Basaran G, Cabuk D, Caglar H,
Abacioglu U, Turhal NS. Outcome of patients with stage III and IV non-small cell lung
cancer in Marmara University Hospital, Istanbul, Turkey. Annals of Oncology Abstract
Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey.
Volume 17, Supp, 9/757P
2.4.1.68. Dane F, Topaloglu N, Abul Y, Yumuk PF, Turhal NS, Ceyhan B, Celikel T,
Caglar H, Basaran G, Ahiskali R. Interstitial pneumonitis associated with Docetaxel
administration. Annals of Oncology Abstract Book of the 31st ESMO Congress 29
September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/1069
2.4.1.69. Demir G, Zengin N, Yildiz O, Dogusoy G, Aykan F, Er O, Isikdogan A, Turhal
NS, Yilmaz U, Yalcin S. The role of lymph nodes on disease free survival in operated
gastric cancer (Turkish Oncology Group Study). Annals of Oncology Abstract Book of the
31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17,
Supp, 9/1100
2.4.1.70. Demir G, Zengin N, Yildiz O, Ozdamar S, Aykan F, Er O, Ilhan M, Turhal NS,
Yilmaz U, Yalcin S. Clinical profile of gastric cancer in Turkey: Factors effecting disease
free survival and relapse (Turkish Oncology Group Study). Annals of Oncology Abstract
Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey.
Volume 17, Supp, 9/1139
2.4.1.71. Basaran G, Guney N, Saip P, Iyikesici S, Kaya H, Yazıcı H, Turhal NS. Serum
extracellular domain (ECD) levels, pAkt and MAKP expressions as potential markers for
response to trastuzumab base therapy in metastatic breast cancer patients: A Turkish
Oncology Group Study. Ann Oncol. 2006 Sept; 17 (Supp 9): ix69–ix92, Abstract 230,
İstanbul, 2006.
2.4.1.72. Yumuk PF, Teomete M, Dane F, Cabuk D, Caglar H, Abacioglu U, Basaran G,
Turhal NS, Outcome of patients with stage III and IV non-small cell lung cancer in
Marmara University Hospital, Istanbul, Turkey. 12 th. World Conference on Lung Cancer.
Journal of Thoracic Oncology, Volume 2, Number 8, Supplement 4, August 2007.
2.4.1.73. M. Gumus, F. Dane, S. Kaya, M. A. Ozturk, P. F. Yumuk, B. M. Atasoy, G.
Basaran, T. Salepci, M. Yaylaci, N. S. Turhal. The role of adjuvant chemoradiotherapy
(CRT) in Turkish patients with gastric carcinoma. Journal of Clinical Oncology, 2007
ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:
15159.
2.4.1.74. F. Dane, M. Gumus, A. Ozturk, F. Yumuk, S. Iyikesici, G. Basaran, D. Cabuk,
M. Teomete, N. S. Turhal. Outcome of metastatic colorectal cancer patients receiving
second line chemotherapy in Marmara University Hospital. Journal of Clinical Oncology,
2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement),
2007: 14588
2.4.1.75. G. Atalay Basaran, D. Cabuk, F. Dane, M. Teomete, S. Iyikesici, E. Meltem, B.
Gulluoglu, H. Kaya, U. Abacıoglu, F. Yumuk, S. Turhal. Clinical outcome of nodenegative (NN) breast cancer (BC) patients. Journal of Clinical Oncology, 2007 ASCO
Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 11102
2.4.1.76. Yumuk PF, Teomete M, Dane F, Cabuk D, Caglar H, Abacioglu U, Basaran G,
Turhal NS, Outcome of patients with stage III and IV non-small cell lung cancer in
33
Marmara University Hospital, Istanbul, Turkey. 12 th. World Conference on Lung Cancer.
Journal of Thoracic Oncology, Volume 2, Number 8, Supplement 4, August 2007.
2.4.1.77. Basaran G, Cabuk D, Teomete M, Gulluoglu B, Kaya H, Dane F, Yumuk PF,
Turhal NS, Benefit from adjuvant anthracyclines according to hormone receptor status.
Annual Meeting ASCO 2008: 11513
2.4.1.78. Turhal NS, Ulus C, Sari S, Senturk N, Bingol D. Cancer-related knowledge in
relatives of cancer patients and general public in İstanbul, Turkey, Annual Meeting ASCO
2008: 20650
2.4.1.79. F Dane, M Gumus, MA Ozturk, D. Cabuk, MB Atasoy, PF Yumuk, G Basaran,
MS Iyikesici, M Teomete, U Abacioglu, NS Turhal. Clinical features and outcome of
adjuvant chemoradiotherapy in Turkish rectal carcinoma patients: Single institution
experience. Annual Meeting ASCO 2008: 15103
2.4.1.80. D Cabuk, G Basaran, H Kaya, B Gulluoglu, M Teomete, F Dane, PF Yumuk,
NS Turhal. Clinical outcome of triple-negative (TN) breast cancer (BC). Annual Meeting
ASCO 2008: 11526
2.4.1.81. Dane F, Gumus M, Yaman E, Ozturk MA, Sevinc A, Atasoy BM, Cabuk D,
Iyikesici S, Yumuk PF, Basaran G, Abacioglu U, Teomete M, NS Turhal, “Demographical
Survival and Prognostic Features of Resected Rectal Cancer in Turkish Patients
Population,” 18th World Congress of the International Association of Surgeons,
Gastroenterologists and Oncologists, İstanbul, Hepato-gastroenterology, Vol. 55, (Suppl.
1), OP70, A28, H.G.E. Update Medical Publishing, Greece, 2008.
2.4.1.82. Cabuk D., Basaran G, Teomete M, Dane F, Yumuk PF, Turhal NS,
“Clinical/pathological characteristics of breast cancer (BC) patients (pts) with triplenegative (TN) tumors,” 7th Congress of Balkan Union of Oncology (BUON), Proceedings,
OP–53, İzmir, 2008.
2.4.1.83. Yumuk PF, Teomete M, Dane F, Cabuk D, Basaran G, Turhal NS, ”Platinum
plus vinorelbine (VNR) on days 1 and 8 in advanced non-small cell lung Cancer: Single
center results,” 7th Congress of Balkan Union of Oncology (BUON), Proceedings, OP–
72, İzmir, 2008.
2.4.1.84. Dane F, Gumus M, Ozturk A, Cabuk D, Basaran G, Turhal NS, “Demographics,
survival and prognostic features of resected colon Cancer in Turkish patients population,”
7th Congress of Balkan Union of Oncology (BUON), Proceedings, OP–92, İzmir, 2008.
2.4.1.85. Dane F, Ozturk A, Gumus M, Yumuk F, Basaran G, Turhal NS, ”Survival and
prognostic features of stage II and III Rectal Cancer (RC) in Turkish patients population,”
7th Congress of Balkan Union of Oncology (BUON), Proceedings, OP–93, İzmir, 2008.
2.4.1.86. Dane F, Gumus M, Cabuk D, Teomete, M, Yumuk PF, Turhal NS, “Prognostic
factors and treatment outcomes in patients with metastatic colorectal cancer (CRC),” 7th
Congress of Balkan Union of Oncology (BUON), Proceedings, OP–94, İzmir, 2008.
2.4.1.87. Civen H, Dede F, Dane F, Ustaoglu MA, Turhal NS, Turoglu H, Inanır S, “Does
the standard test parameters for C-14 urea breath test really work in partially
gastrectomised patients with gastric cancer,” Annual Congress of the European
Association of Nuclear Medicine, Eur. J. Nucl. Med., 35, S238, Münih, 2008.
34
2.4.1.88. Yumuk PF, Teomete M, Dane F, Cabuk D, Basaran G, Turhal NS, Impact of
dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung
cancer (NSCLC). 2009 ASCO Annual Meeting, J Clin Oncol 27, 2009 (suppl; abstr
e19055),
2.4.1.89. Turhal NS, Yurt N, Yurtseven G, Cabuk D, Teomete M, Gumus M. Weight
gain after adjuvant treatment in breast cancer patients in Istanbul, Turkey. 2009 ASCO
Annual Meeting, J Clin Oncol 27, 2009, (suppl; abstr e11620),
2.4.1.90. Abali H, Ata A, Turhal NS, Ozdogan M, Seyrek E, Erman M, Celik I. Frequency
of co-morbid illnesses in cancer patients in Turkey. 2009 ASCO Annual Meeting, J Clin
Oncol 27, 2009, (suppl; abstr e20717),
2.4.1.91. Kefeli U, Yumuk PF, Ceyhan B, Dane F, Eroglu B, Cabuk D, Basaran G,
Teomete M, Turhal NS, Pulmonary toxicity in patients receiving docetaxel
chemotherapy. 2009 ASCO Annual Meeting, J Clin Oncol 27, 2009, (suppl; abstr
e13532),
2.4.1.92. Turhal NS, Dane F, Seber S, Korkmaz T, Cabuk D, Basaran G, Yumuk F,
Caglar H, Atasoy B. “Challenges in applicability of Standard treatment for head and neck
cancer patients in Istanbul”. Euroasian Congress on Head & Neck Oncology, Minsk,
Republic of Belarus, 16-19 July 2009, Becthиk POHц им. H. H. Блoина, Proceedings,
20(2), 2009: 116.
2.4.1.93. Cabuk D, Basaran G, Korkmaz T, Seber S, Dane F, Telli F, yumuk F, Turhal
NS. Clinical outcome of Turkish metastatic breast cancer patients with currently available
treatment modalities. European Breast Cancer Conference 7, 24-30 March 2010
Barcelona. Eur J Cancer Supplements, Vol . 8, No 3, p205, Poster 498 (2010)
2.4.94. Turhal NS, Basaran G, Yurt N, Yurtseven G, Cabuk D, Teomete M, Gumus M.
Weight Gain after Adjuvant Chemotherapy in Early Breast Cancer Patients in Istanbul
Turkey. American Society of Clinical Oncology 2010 Annual Meeting June 4-8 2010
2.4.1.95. Basaran G, Cabuk D, Korkmaz T, Kocar M, Telli F, Dane F, Yumuk F, Turhal
NS. Clinical, pathological factors predicting early relapse in hormone receptor early
breast cancer. BUON Congress 2010, Best Abstracts Presented at BUON Congress
2010,Proceedings Book, 8-11 September 2010, Sibiu, Romania. BA 28, page 13
2.4.1.96. Turhal NS, Dane F, Seber S, Korkmaz T, Yumuk F, Kanitez M, Telli F, Kocar
M, Basaran G. Tolerability of anthracyclines in Turkish breast cancer patients. BUON
Congress 2010, Proceedings Book, 8-11 September 2010, Sibiu, Romania. Oral
presentation OP-32, page 14
2.4.1.97. Ozturk MA, Dane F, Karagoz S, Tural D, Demirelli F, Basaran G, Buyukunal E,
Mandel NM, Ç Erdamar S, Turna H, Seber S, Turhal NS, Serdengecti S. The prognostic
value of perineural invasion in patients with early stage colon cancer. BUON Congress
2010, Best Abstracts Presented at BUON Congress 2010,Proceedings Book, 8-11
September 2010, Sibiu, Romania. BA 65, page 23
2.4.1.98. Turhal NS, Kilickap S, S Yalcin, C Sezgin, D Yamac, H Akbulut, O Ozyilkan, F
Ozdemir, D Cabuk, A Sevinc. The association between sociodemographic parameters
and the use of complementary interventions in patients with cancer in Turkey: A Turkish
Oncology Group study. 2011 ASCO Annual Meeting, J Clin Oncol 29: 2011 (suppl; abstr
e19598)
35
2.4.1.99 T. Korkmaz, S. Seber, G. Basaran, P.F. Yumuk, F. Dane, K. Okutur, M. Kanitez,
M. Kocar, F. Telli, G. Demir, Turhal NS. Prognostic significance of serum thymidine
kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC).
2011 ASCO Annual Meeting. J Clin Oncol 29: 2011 (suppl; abstr e18010).
2.4.1.100. S. Seber, G. Basaran, T. Korkmaz, F. Telli, M. Kocar, M. Kanitez, F. Dane,
P.F. Yumuk, Turhal NS. Clinical / pathologic characteristics of diabetic patients with early
breast cancer (BC) and their survival outcome. 2011 ASCO Annual Meeting. J ClinOncol
29: 2011 (suppl; abstr e11019)
2.4.1.101. Turhal NS, Dane F, Butur S, Kocak M, Telli F, et al. Efforts to Validate the
Applicability of Established Chemotherapy Treatment in Turkish Cancer Patients. Pharm
Anal Acta S14. 2011. doi:10.4172/2153-2435.S14-001.
2.4.1.102. Dane F, Ozturk MA, Koçar M, Atasoy BM, Aktas B, Telli F, Kanitez M,
Beşiroğlu M, Yumuk PF, Turhal NS. Prognostic significance of combined positivity of
lymphatic, vascular, and perineural invasion (triple positive) in stage ii/iii colorectal
cancer; a new paradigm worth to investigate? ESMO 2012, Abstract: 547P
2.4.1.103. Atasoy BM, Cetin IA, Bozkurt SU, Turhal NS. Metastasis to Paranasal
Sinuses and Orbita of Breast Cancer With a Rare Metachronous Tumor of the Uterine
Cervix. The Journal of Craniofacial Surgery. Vol. 24 No. 1-e64 January 2013
2.4.2. Ulusal bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler:
Ulusal kongre / sempozyumlarda sunulan diğer bildiriler:
A. DOÇENTLİK SONRASI
2.4.2.1. Dincbas FO, Koca S, Altınel A, Hancılar T, Cavusoglu M, Turhal S, Uskent N,
Ozguroglu M, Okkan S. “Evre III küçük hücreli dışı akciğer kanserinde (KHDAK) aralıksız
hızlandırılmış hiperfraksiyone radyoterapi (CHART) ve kemoterapi çalışması (TOG-011
çalışması – Erken sonuçlar)” Bildiri Özetleri, XIV. Ulusal Kanser Kongresi (Uluslararası
katılımlı). SB-06 s: 62. İstanbul, 2001
2.4.2.2. Abacıoglu U, Sengoz M, Caglar H, Gumus M, Atalay G, Turhal S. “Rektum ve
sigmoid kanserlerinde adjuvan kemoradyoterapi sonuçları” Bildiri Özetleri, XIV. Ulusal
Kanser Kongresi (Uluslararası katılımlı), SB-07 s: 64. İstanbul, 2001
2.4.2.3. Guler N, Yucel I, Ozet A, Bilkay BC, Erkisi M, Onur H, Buyukunal E, Turhal S,
Firat D. “Metastatik meme kanserinin birinci basamak tedavisinde Vinorelbin Epirubisin 5Fluorourasil kombinasynu” Bildiri Özetleri, XIV. Ulusal Kanser Kongresi (Uluslararası
katılımlı). SB-09 s: 69. İstanbul, 2001
2.4.2.4. Gumus M, Atalay G, Aliustaoglu M, Karamanoglu A, Dane F, Turhal NS. “
Marmara Üniversitesi Hastanesi’nde izlenen evre II ve evre III kolon kanserli hastaların
değerlendirilmesi” Bildiri Özetleri, XIV. Ulusal Kanser Kongresi (Uluslararası katılımlı).
SB-14 s: 84. İstanbul, 2001
36
2.4.2.5. Gumus M, Atalay G, Aliustaoglu M, Karamanoglu A, Turhal NS. “Marmara
Üniversitesi Hastanesi’nde izlenen evre IV kolon kanserli hastaların değerlendirilmesi”
Bildiri Özetleri, XIV. Ulusal Kanser Kongresi (Uluslararası katılımlı). SB-14 s: 85. İstanbul,
2001
2.4.2.6. Aliustaoglu M, Atalay G, Gumus M, Karamanoglu A, Turhal NS. “ Marmara
Üniversitesi Hastanesi’nde izlenen evre III B-IV küçük hücreli dışı akciğer kanserli
hastaların sürvi karakteristiklerinin değerlendirilmesi” Bildiri Özetleri, XIV. Ulusal Kanser
Kongresi (Uluslararası katılımlı). PO-05 s: 187. İstanbul, 2001
2.4.2.7. Dane F, Turhal NS, Gumus M, Dede F, Sengoz M, Yumuk F, Turoglu T. Tc-99m
MDP scintimammography in the detection of breast lesions. Turkish Journal of Nuclear
Medicine Volume 11(1), 2002: 47.
2.4.2.8. Dane F, Turhal NS, Gumus M, Dede F, Cakalagaoglu F, Yumuk F, Turoglu T.
Correlation between Tc-99m MDP uptake and prognostic factors in breast cancer.
Turkish Journal of Nuclear Medicine Volume 11, 2002: 11
2.4.2.9. Komurcu S, Turhal NS, Altundag K, Atahan L, Savas-Turna H, Manavoglu O,
Yavuz AA, Ozkok S, Aliustaoglu M, Altınbas M. “A clinical evaluation of transdermal
fentanyl in adults with cancer pain: Phase IV, multicentre trial”. Program ve Bildiri Özet
Kitabı XV. Ulusal Kanser Kongresi , , P079 ref 0381 s:48. Antalya, 2003.
2.4.2.10. Aliustaoğlu, M., Turhal, S., Ekenel, M., Gümüş, M. ve Yumuk PF, “Evre IIII over
kanserinde kemoterapi sonuçlarımız”, Program ve Bildiri Özet Kitabı, XV. Ulusal Kanser
Kongresi, P290, Antalya, 2003.
2.4.2.11. Gümüş, M., Dane, F., Aliustaoğlu, M., Yumuk, P.F., Ekenel, M., Selepçi, T., Barışık,
N. ve Turhal NS, “Meme kanserli hastalarda normal ve tümoral doku örneklerinde human
papillomavirus (HPV) DNA sıklığı ve HPV tip tayini”, Kurs ve bildiri özet kitabı, VII. Ulusal
Meme Hastalıkları Kongresi, s: 44, Antalya, 2003.
2.4.2.12. Ekenel, M., Başaran, G., Gümüş, M., Aliustaoğlu, M., Dane F., Yumuk, P.F. ve NS
Turhal, “Premenopozal meme kanseri hastalarında kemoterapiye bağlı amenore insidansı ve
prognostic rolü”, Kurs ve Bildiri Özet Kitabı, VII. Ulusal Meme Hastalıkları Kongresi, P82,
Antalya, 2003.
2.4.2.13. Abacıoğlu, U., Odabaş, Ö.F., Tezcanlı, E., Çağlar, H., Yumuk, P.F., Şengöz, M. ve
Turhal S, “Kolorektal Kanserli Hastaların Yaşam Kalitesini Değerlendirmede EORTC
Kolorektal Kanser Modülü QLQ-CR38’in Türkçe Çevirisi ve Pilot-Test Çalışması”, Bildiri Özet
Kitabı, VI. Ulusal Radyasyon Onkolojisi Kongresi, P45, Antalya, 2004.
2.4.2.14. Çağlar, H., Abacıoğlu, U., Tezcanlı, E., Yumuk, F., Turhal, S. ve M. Şengöz,
“Lokal ileri evre pankreas kanserli hastalarda radyoterapi ve eş zamanlı gemsitabin
tedavisinin toksisite ve sağkalım sonuçları”, Bildiri Özet Kitabı, VI. Ulusal Radyasyon
Onkolojisi Kongresi, P48, Antalya, 2004.
2.4.2.15. Küçük hücreli dışı akciğer kanseri nedeniyle izlenen yaşlı hastalarda
kemoterapi. Palak B, Gümüş M, İyikesici S, Şeker M, Topal A, Yumuk F, Salepçi T, Yayla
A, Turhal NS, 1. Ulusal Torasik Onkoloji Kongresi, Antalya,Final Program ve Bildiri Özet
Kitabı, S78, Antalya, 2004.
2.4.2.16. Yumuk PF, İyikesici S, Gumus M, Aliustaoglu M, Dane F, Başaran G, Ekenel M,
Abacıoglu U, Turhal NS. “Kemoterapi verilen lokal ileri ve metastatik küçük hücreli dışı
akciğer kanseri hastalarının sağ kalım ve prognostik açıdan değerlendirilmesi” Final
Program ve Bildiri Özet Kitabı, 1. Ulusal Torasik Onkoloji Kongresi, S79 Antalya, 2004.
37
2.4.2.17.Yumuk PF, Gümüş M, Dane F, Kaya H, Alam K, İyikesici MS, Güllüoğlu B,
Ekenel M, Atalay G, Turhal NS, “Meme kanseri hastalarında HPV-DNA ampfilikasyonu
ve P53 ekspresyonunun prognostik değeri” Program ve bildiri özet kitabı, XVI. Ulusal
Kanser Kongresi, Ref 873, Antalya, 2005.
2.4.2.18. Yalçın B, Aydın F, Zengin N, İlhan M, Demir G, Bozcuk H, Çelik İ, Turhal NS,
İçli F, Işıkdoğan A, “Türkiye’de mide kanserli hastaların klinik patolojik özellikleri: Çok
merkezli retrospektif çalışma (Türk Onkoloji Grubu)” Program ve bildiri özet kitabı, XVI.
Ulusal Kanser Kongresi, Ref 601, Antalya, 2005.
2.4.2.19. Akgün Z, Çetin İ, Karaüç, Çağlar H, Abacıoğlu U, Dane F, Yumuk PF, Şengöz
M, Turhal NS, “Mide adenokarsinomlarında cerrahi rezeksiyon sonrasında adjuvan
kemoradyoterapi sonuçlarımız” Program ve bildiri özet kitabı, XVI. Ulusal Kanser
Kongresi, Ref 708, Antalya, 2005.
2.4.2.20. Çetin İ, Akgün Z, Abacıoğlu U, Şengöz M, Yumuk PF, Turhal NS, “Lokal ileri
evre özafagus kanserli hastalarda primer kemoradyoterapi sonuçları” Program ve bildiri
özet kitabı, XVI. Ulusal Kanser Kongresi, Ref 822, Antalya, 2005.
2.4.2.21. Çetin İ, Akgün Z, Çağlar H, Tezcanlı E, Abacıoğlu U, Şengöz M, Yumuk PF,
Turhal NS, Türkeri L, “Mesane tümörlü hastaların kemoradyoterapi sonuçları” Program
ve bildiri özet kitabı, XVI. Ulusal Kanser Kongresi, Ref 806, Antalya, 2005.
2.4.2.22. İyikesici MS, Yumuk PF, Dane F, Başaran G, Ekenel M, Abacıoğlu U, Şengöz
M, Turhal NS, “Marmara Üniversitesi Hastanesindeki Evre III ve IV küçük hücreli dışı
akciğer kanserli hastaların sonuçları” Program ve bildiri özet kitabı, XVI. Ulusal Kanser
Kongresi, Ref 805, Antalya, 2005.
2.4.2.23. Turhal NS, Yumuk PF, İyikesici MS, Dane F, Başaran G, Ekenel M, Avery B,
“Knoxville, Tennessee, USA’da evre III ve IV küçük hücreli dışı akciğer kanserli hastaların
sonuçları. Program ve bildiri özet kitabı, XVI. Ulusal Kanser Kongresi, Ref 812, Antalya,
2005.
2.4.2.24. Meme kanserli hastaların metastaz yönünden tüm vücut MR incelemesi ile
değerlendirilmesi: Ön çalışma. Dane F, Güran S, İyikesici S, Atalay G, Yumuk F, Turhal
NS, 8. Ulusal Meme Hastalıkları Kongresi, İstanbul, Kongre Özet Kitabı, 21-24 Eylül
2005, P161.
2.4.2.25. Cabuk D, Basaran G, Yumuk PF, Celikel C, Dane F, Iyikesici MS, Ekenel M,
Turhal NS, “Mide kanserinde VEGF, HIF- Alfa, CD34 Ekspresyonu ve bu faktörlerin
prognostik önemi”. Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi, SB 03, Antalya,
2006.
2.4.2.26. Komurcu S, Turhal NS, Altundag K, Atahan L, Turna H, Manavoglu O, Yavuz
A, Ozkok S, “Transdermal fentanilin kanser ağrısı olan hastalarda etkinliğinin ve
güvenliğinin değerlendirilmesi: FAZ IV, TOG destek tedaviler çalışma grubu”, Program ve
Özet Kitabı. I. Tıbbi Onkoloji Kongresi, SB 21, Antalya, 2006.
2.4.2.27. Dane F, Yumuk PF, Iyikesici MS, Gumus M, Tufan A, Basaran G, Teomete M,
Turhal NS, “Palyatif kemoterapi alan metastatik kolorektal kanser hastalarının sağ kalım
sonuçları” Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi, SB 42, Antalya, 2006.
38
2.4.2.28. Dane F, Gümüş M, İyikesici S, Yumuk F, Öztürk A, Başaran G, Çabuk D,
Turhal NS, Adjuvan Kemoterapi alan Kolon Kanseri Hastalarının Sağkalım ve Prognostik
Açıdan Değerlendirilmesi. 1. Tıbbi Onkoloji Kongresi, Antalya, Bildiri Özet Kitabı, 29 Mart
- 2 Nisan 2006, P066.
2.4.2.29. Dane F, Gumus M, Iyikesici MS, Yumuk PF, Basaran G, Atasoy B, Abacioglu U,
Turhal NS, “Adjuvan kemoradyoterapi verilen evre II/III rektum kanseri hastalarının sağ
kalım ve prognostik açıdan değerlendirilmesi”, Program ve Özet Kitabı. I. Tıbbi Onkoloji
Kongresi, SB 45, Antalya, 2006.
2.4.2.30. Atasoy BM, Abacioglu U, Ozgen Z, Dane F, Yumuk PF, Mayadagli A, Turhal
NS, Sengoz M, “Rektum kanserinin adjuvan tedavisinde radyoterapiyle eş zamanlı
Tegafur-Urasil (UFT) / Folinik Asit (FA) uygulaması: Tolerabilite değerlendirmesi”
Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi, SB 46, Antalya, 2006.
2.4.2.31. Atasoy BM, Abacıoğlu U, Özgen Z, Dane F, Yumuk PF., Mayadağlı A, Turhal
NS ve M. Şengöz, “Rektum Kanserinin adjuvan tedavisinde radyoterapiyle eş zamanlı
Tegafur-Urasil (UFT)/Folinik asit (FA) uygulanması: Tolerabilite Değerlendirilmesi,” VII.
Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı, S13, Fethiye, 2006.
2.4.2.32. Dane F, Gumus M, Iyikesici MS, Yumuk PF, Ozturk A, Basaran G, Cabuk D,
Turhal NS, “Adjuvan kemoterapi alan kolon kanseri hastalarının sağ kalım ve prognostik
açıdan değerlendirilmesi”, Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi, P 066,
Antalya, 2006.
2.4.2.33. Öztürk A, Dane F, Tecimer T, Atasoy B, Çabuk D, Yumuk PF, Başaran G,
Teomete M, Turhal NS. “Onkoloji Kliniğine Refere edilen Selim Bir Lenf Adenopati
Nedeni: Kikuchi-Fujimoto Hastalığı” 4. Ulusal Tıbbi Onkoloji Kongresi Özet Kitabı” B 62,
Antalya, 5-9 Eylül 2007.
2.4.2.34. Dane F, Gumus M, Ozturk MA, Atasoy BM, Iyikesici S, Yumuk PF, Basaran G,
Abacıoglu U, Cabuk DO, Teomete M, Turhal NS. Rektum kanseri olgularanın klinik
özellikleri ve adjuvant kemoradyoterapi sonuçları: Tek merkez tecrübesi. Tıbbi Onkoloji
Kongresi Antalya. 26-30 Mart 2008.
2.4.2.35. Öztürk A, Dane F, Tecimer T, Atasoy B, Çabuk D, Yumuk PF, Başaran G,
Teomete M, Turhal NS. “Onkoloji Kliniğine Refere edilen Selim Bir Lenf Adenopati
Nedeni: Kikuchi-Fujimoto Hastalığı” 4. Ulusal Tıbbi Onkoloji Kongresi Özet Kitabı” B 62,
Antalya, 5-9 Eylül 2007.
2.4.2.36. Gümüş M, Dane F, Kaya S, Öztürk MA, Yumuk PF, Atasoy BM, Başaran G,
Salepçi T, Yaylacı M, ve Turhal NS, “Mide Kanserinin Adjuvan Tedavisinde
Kemoradyoterapinin Etkinliği,” 17.Ulusal Kanser Kongresi, Bildiri Özet Kitabı, Ref No: 774
Antalya, 2007.
2.4.2.37. Yamaç D, Turhal NS, Karaca B, Coşkun HŞ, Kömürcü Ş, Yavuzşen T, Dane F,
Yaman E, Nalça M, ve M. Akmansu, “Kanser Tanısını Söyleme Yöntemimizi Sorgulama,”
2.Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, SB29 (Sözlü Bildiri), Antalya, 2008.
2.4.2.38. Dane F, Gümüş M, Öztürk MA, Atasoy BM, İyikesici S, Yumuk PF, Başaran G,
Abacıoğlu U, Çabuk DÖ, Teomete, M ve Turhal NS, “Rektum Kanseri Olgularının Klinik
Özellikleri ve Adjuvan Kemoradyoterapi Sonuçları: Tek Merkez Tecrübesi,” 2.Tıbbi
Onkoloji Kongresi, Bildiri Özet Kitabı, P23, Antalya, 2008. [Poster Bildiri Ödülü]
2.4.2.39. Dane F, Gümüş M, Yaman E, Öztürk MA, Sevinç A, Atasoy BM, Çabuk D,
İyikesici S, Yumuk PF, Başaran G, Abacıoğlu U, Teomete M ve Turhal NS, “Türk
Toplumunda Rektum Kanserli Hastaların Demografik, Histopatolojik Özellikleri, Sağ
39
Kalım ve Prognostik Faktörler,” 5. Ulusal Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, B42,
Antalya, 2008.
2.4.2.40. Atasoy BM, Dane F, Çağlar H, Cingi A, Abacıoğlu U, Turhal NS, Şengöz M ve
C. Yeğen, “Rezeke Edilebilir Lokal İleri Evre Rektum Kanserinde Preoperatif
Radyoterapiyle Eş Zamanlı Floropirimidin Uygulaması: Oral mi, İntravenöz mü?,” VIII.
Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı, 184, Antalya, 2008.
2.4.2.41. Dane F, Gümüş M, Yaman E, Öztürk MA, Sevinç A, Atasoy BM, Çabuk D,
İyikesici S, Yumuk PF, Başaran GA, Abacıoğlu U, Teomete M, Turhal NS, Küratif olarak
rezeke edilmiş evre II-III rektum kanserli Türk hasta populasyonunun adjuvan
kemoradyoterapi sonuçları, prognostik özellikleri ve sağkalım analizleri, çok merkezli
retrospektif çalışma. Marmara Üniversitesi Tıp Fakültesi 3. Araştırma Günleri, İstanbul,
Marmara Medical Journal 21(Ek 1) (2008), 9.
2.4.2.42. Öztürk MA, Dane F, Çelikel ÇA, Baş E, Çabuk D, Yumuk PF, Başaran GA.,
Teomete M ve Turhal NS, “Adjuvan Kemoradyoterapi alan Kolorektal Kanser
Hastalarında Survivinin Prognostik Önemi,” 18. Ulusal Kanser Kongresi, Bildiri Özet
Kitabı, P135, Antalya, 2009.
2.4.2.43. Dane F, Öztürk MA, Gümüş M, Çabuk D, Yumuk PF, Başaran G, Teomete M,
Korkmaz T, Şeber S, ve Turhal NS, “Metastatik Kolorektal Kanser Tedavisinde
Bevasizumab: Geç daha mı az etkin?,” 18. Ulusal Kanser Kongresi, Bildiri Özet Kitabı,
P139, Antalya, 2009.
2.4.2.44. Dane F, Demir G, Öztürk MA, Yeğen C, Çabuk D, Başaran G, Yumuk PF,
Teomete M, Korkmaz T, Şeber S ve Turhal NS, “Karaciğer ve akciğer metastazlı
kolorektal kanser hastalarında cerrahi rezeksiyon sonuçları,” 18. Ulusal Kanser Kongresi,
Bildiri Özet Kitabı, P149, Antalya, 2009.
2.4.2.45. Atasoy BM, Dane F, Akgün Z, Çabuk D, Kabalay İA, Yumuk PF, Çağlar H,
Turhal NS ve U Abacıoğlu, “Lokal ileri evre nazofarenks kanserinde dosetaksel ile
sisplatin bazlı indüksiyon kemoterapisi sonrası sisplatinle eş zamanlı kemoradyoterapi:
Sağkalım ve yan etki değerlendirmesi,” 18. Ulusal Kanser Kongresi, Bildiri Özet Kitabı,
P236, Antalya, 2009.
2.4.2.46. Turhal NS, PF Yumuk, MS iyikesici, F Dane, G Başaran, M Ekenel, Bruce
Avery. Knoxville, tennessee USA’de Evre III ve IV küçük hücreli dışı akciğer kanserli
hastaların sonuçları. 18. Ulusal Kanser Kongresi, Bildiri Özet Kitabı, Ref 812; 72, Antalya,
2009
2.4.2.47. Adjuvan kemoradyoterapi (AKRT) alan kolorektal kanser (KRK) hastalarında
survivinin prognostik önemi. Öztürk MA, Dane F, Demirel ÇA, Baş E, Çabuk D, Yumuk
PF, Başaran G, Teomete M, Turhal NS, Marmara Üniversitesi Tıp Fakültesi 3. Araştırma
Günleri, İstanbul, Marmara Medical Journal 22(1)(Ek 1) (2009), 6.
2.4.2.48. Basaran GA, Şeber S, Çabuk D, Korkmaz T, Turhal NS, Dane F, Başaran M,
Koçak M, Telli F, Yumuk F. Erken evre meme kanserli hastalarda adjuvan trastuzumab
tedavisi alan hastalarımızın klinik seyri. III. Tıbbi Onkoloji Kongresi Bildiri Kitabı, Poster
150, sayfa 97; 24-28 Mart 2010 Antalya
2.4.2.49. Şeber ES, Başaran G, Çabuk D, Korkmaz T, Koçar M, Telli F, Dane F, Yumuk
F, Turhal NS. Trastuzumab sonrası progrese olan metastatik meme kanseri
hastalarımızda lapatinib kullanımı. Erken evre meme kanserli hastalarda adjuvan
trastuzumab tedavisi alan hastalarımızın klinik seyri. III. Tıbbi Onkoloji Kongresi Bildiri
Kitabı, Poster 121, sayfa 84; 24-28 Mart 2010 Antalya
40
2.4.2.50. Çabuk D, Başaran G, Dane F, Korkmaz T, Şeber S, Telli F, Yumuk F, Turhal
NS, metastatik meme kanseri hastalarının kl,inik özellikleri ve sağkalım sonuçları: Tek
merkez deneyimi. III. Tıbbi Onkoloji Kongresi Bildiri Kitabı, Poster 146 sayfa 95; 24-28
Mart 2010 Antalya
2.4.2.51. Dane F, Öztürk MA, Ozkan M, Yıldız OG, Yaman E, Sevinç A, Atasoy BM,
Gümüş M, Koçar M, Başaran G, Yumuk PF, Turhal NS. Günlük pratikte tedavi alan
rektum kanseri hastalarının demografik sağkalım ve klinik/patolojik özellikleri: retrospektif
bir kohort çalışması. VII. Ulusal Tıbbi Onkoloji Kongresi. Kongre Bildiri Kitabı. Poster 86,
sayfa 139, 22-26 Eylül 2010, Antalya,
2.4.2.52. Dane F, Öztürk MA, Koçar M, Çabuk D, Teomete M, Korkmaz T, Seber S, Telli
F, Kanıtez M, Başaran G, Yumuk PF, Turhal NS. Müsin varlığı evre II kolorektal
kanserlerde bağımsız bir risk faktörüdür. Kongre Bildiri Kitabı.poster no 88, sayfa 141 VII.
Ulusal Tıbbi Onkoloji Kongresi 22-26 Eylül 2010, Antalya,
2.4.2.53. Dane F, Öztürk MA, Atasoy BM, Gümüş M, Koçar M, Çabuk D, Teomete M,
Başaran G, Yumuk PF, Çelikel Ç, Turhal NS. Erken Evre rektum kanserlerinde perinöral
invazyonun prognostik önemi. Kongre Bildiri Kitabı poster no 89, sayfa 142. VII. Ulusal
Tıbbi Onkoloji Kongresi 22-26 Eylül 2010, Antalya,
2.4.2.54. Şeber ES, Başaran G, Korkmaz T, Telli F, Kocar M, Kanıtez M, Aktaş B, Dane
F, Yumuk PF, Turhal NS. Diyabetik Erken Evre Meme Kanserli Hastaların Klinik /
Patolojik Özellikleri ve Sağ kalım Verileri. Bildiri Özetleri, 19. Ulusal Kanser Kongresi 2024 Nisan 2011, Antalya. P 229
2.4.2.55. Aktas B, Dane F, Seber S, Telli F, Koçar M, Kanıtez M, Beşiroğlu M, Yumuk PF,
Turhal NS, Böbrek hücreli tümörde mide metastazı: Olgu sunumu. 4. Tıbbi Onkoloji
Kongresi. EP-266 Sf: 261 21-25 Mart 2012, Antalya
2.4.2.56. Seber S, Korkmaz T, Okutur K, Kanıtez M, Aktas B, Telli F, Koçar M, Beşiroğlu
M, Yumuk PF, Turhal NS, Metastatik Kolorektal Kanserinde Kemoterapi Öncesi Timidin
Kinaz Aktivite Düzeylerinin Prognostik Önemi. 4. Tıbbi Onkoloji Kongresi. EP-174 Sf: 220
21-25 Mart 2012, Antalya
2.4.2.57. Korkmaz T, Seber S, Aydın D, Ustaalioğlu B, Canhoroz M, Bilici A, Yıldız R,
Yaşar N, Ercelep Ö, Şener N, Güven A, Yüksel S, Yumuk PF, Kanat Ö, Gümüş M,
Turhal NS, Küçük Hücreli Akciğer Kanserinde 2. Basamak Tedavi Etkinliğinin Çok
Merkezli ve Retrospektif Olarak İncelenmesi. 4. Tıbbi Onkoloji Kongresi. EP-23 Sf: 151
21-25 Mart 2012, Antalya
2.4.2.58. Öztürk MA, Dane F, Karagöz S, Tural D, Turna H, Büyükünal E, Erdamar S,
Turhal NS, Serdengeçti S. Adjuvan Tedavi Verilen Kolorektal Kanserlerde (KRK)
Perinöral İnvazyonun (PNI) Hastalıksız Sağ Kalım (DFS) Açısından Önemi. 4. Tıbbi
Onkoloji Kongresi. S-11 Sf: 112 21-25 Mart 2012, Antalya
2.4.2.59. Koçar M, Dane F, Yumuk PF, Telli F, Seber S, Kanıtez M, Turhal NS,
Metastatik Böbrek Hücreli Kanserde Sunitinib Tedavisinin Etkinlik ve Yanetki Profilinin
Değerlendirilmesi. 4. Tıbbi Onkoloji Kongresi. EP-350 Sf: 299. 21-25 Mart 2012, Antalya
2.4.2.60. Hayran M, Kılıçkap S, Elkıran T, Akbulut H, Abalı H, Yüce D, Kılıç D, Turhal
NS, Kanserli Hasta Yakınlarında Sigara İçme Alışkanlıkları. 4. Tıbbi Onkoloji Kongresi.
EP-135 Sf: 201 21-25 Mart 2012, Antalya
2.4.2.61. Dane F, Atasoy BM, Akgün Z, Yumuk PF, Çabuk D, Teomete M, Başaran G,
Turhal NS, Abacıoğlu U. Evre III/IV Non Metastatik Nazofarenks Kanserinde Sisplatinle
41
Eş Zamanlı Kemoradyoterapi Öncesi Dosetaksel ile Sisplatin Bazlı İndüksiyon
Kemoterapisi. 4. Tıbbi Onkoloji Kongresi. SS-1 Sf: 102. 21-25 Mart 2012, Antalya
2.4.2.62. Yurtseven G, Yurt N, Aygün M, Turhal NS, Onkolojik Tedavi Sonrası Takibe
Uyum 4. Tıbbi Onkoloji Kongresi. HS-8 Sf: 136 21-25 Mart 2012, Antalya
2.5. Makale ve bildiri dışı diğer yayınlar:
2.5.2. Türkçe kitap yazarlığı:
2.5.2.1. Turhal NS, “Antineoplastik İlaçları Kullanma Rehberi” İstanbul 1999.
2.5.3. Yabancı dilde kitap bölümü yazarlığı:
2.5.3.1. Biochemistry of Cancer, Medical Oncology Board Review, Williams & Wilkins,
Philadelphia 1-42 March 1997.
2.5.3.2. Lung Cancer, Medical Oncology Board Review, Williams & Wilkins,
Philadelphia 107-209 March 1997.
B. DOÇENTLIK SONRASI
2.5.3.3. Turhal NS, Yumuk PF, “Tumor markers in neuroendocrine tumors of the
gastroenteropancreatic system” İstanbul, 2004.
2.5.4. Türkçe kitap bölümü yazarlığı:
2.5.4.1. Gümüş M, Atalay G, Aliustaoğlu M, Turhal NS, “Kolorektal Kanser (Bağırsak
Kanseri) Hasta El Kitabı, İstanbul, 2000.
2.5.4.2. Atalay G, Aliustaoğlu M, Gümüş M, Turhal NS, “Meme Kanseri Hasta El
Kitabı”, İstanbul, 2001.
2.5.4.3. Aliustaoğlu M, Gümüş M, Atalay G, Turhal NS, “Akciğer Kanseri Hasta El
Kitabı”, İstanbul, 2001.
2.5.4.4. Turhal NS, “Özafagus kanserinde kemoterapi ve kemoradyoterapi
uygulamaları” Özafagus hastalıklarının tıbbi ve cerrahi tedavisi, ed. Prof. Dr. Mustafa
Yüksel, Prof. Dr. Ahmet Başoğlu, 321-329, İstanbul 2002.
2.5.4.5. Turhal NS, “Yüksek riskli gestasyonal trofoblastik tümörlerin tedavisi”,
Jinekolojik Kanserlerde Tedavi, ed. N.M. Mandel ve M. Özgüroğlu, 89-96, Frekans,
İstanbul, 2004.
2.5.4.6. Dane F, Ekenel M, Başaran G, İyikesici MS, Yumuk PF, Karamanoğlu A,
Turhal NS. “Onkoloji Hastalarında Beslenme ve Egzersiz Rehberi” İstanbul 2004.
42
2.5.4.7. Turhal NS, Yumuk PF. “Karaciğer, safra kesesi ve safra yolları kanserleri”.
İç Hastalıkları, Cilt 1, Ed. Ç. Erol, 359-366, MN Medikal & Nobel Tıp Kitap Sarayı,
Ankara 2008. ISBN No: 978-975-567-051-5
2.7. Oturum başkanı veya konuşmacı olarak yer alınan bilimsel toplantılar:
2.7.1. Uluslararası bilimsel toplantılar:
2.7.1.1. “Approach to Colorectal cancer in Balkans”, Balkan Congress of Oncology,
Serbia/Belgrad, September 2004
2.7.1.2. “Current Approach to Hepatocellular Cancer” Hazar University Multidisiplinary
liver disease meeting. Azerbaijan/Bakü, November 2004
2.7.1.3 “Current Treatment of Non-Hodgkin Lymphomas” King Faisal Medical Center.
Saudi Arabia/Riyadh November 2005
2.7.1.4. “New approaches to the treatment of brain metastasis” Turkish-Hellenic
ESMO Advanced Course. Recent Advances in the Treatment of Cancer.
Turkey/Istanbul, December 2005
2.7.1.5. “Applications of Regenerative Medicine in Turkey” Regional Health
Conference “Balkan Medicine towards New Millenium” Romania/Bcharest, May 2006
2.7.1.6. “New Research Efforts for Metastatic Gastric Cancer”
Gastrointestinal Tract Cancer Collaborative Group, France/Paris, May 2006
EORTC
2.7.1.7. Moderator, Balkan School of Oncology, Second Seminar for Molecular
Oncology in Cancer. Greece/Volos September 2007.
2.7.1.8. Moderator, Innovative Therapetic Approaches in Non-Colorectal Cancer,
European Organization for research and Treatment of Cancer Gastrointestinal Tract
Cancer Collaborative Group, Germany/Mainz November 2007
2.7.1.9. Moderator, Rare Gastrointestinal Tumors, Turkish-Hellenic 3rd ESMO
Advanced Course Turkey/Istanbul December 2007
2.7.1.10. European Organization for Research and Treatment of CancerGastrointestinal Tract Cancer Group Meeting Mainz, Germany. November 8-11th,
2007.
2.7.1.11. The mesothelioma problem in Turkey. Malignant Mesothelioma in The
Twenty First Century. National Cancer Institute Cairo February 20-23rd, 2008. Cairo
Egypt
2.7.1.12. The breast cancer patient characteristics in Marmara University Istanbul,
Turkey. The Multidisciplinary Approach to the Breast Cancer. The Baruch Padeh
Medical Center Poriya, Israel March 5th, 2008
43
2.7.1.13. The Introduction to Cancer Chemotherapy and Pharmacology. The 2nd
ASCO SEMCO Conference. Ain Shams University Cairo, Egypt. March 26-28th, 2008.
2.7.1.14. Baş Boyun kanseri hastalarına standart tedavi uygulanmasında karşılaşılan
güçlükler. II Eurasian Melanoma&Skin Cancer Forum. 25-28 Temmuz 2013. St.
Petersburg, Rusya
2.7.1.15. Türk Kanser Hastalarında Kemoterapi Etkinliğini Doğrulama Çabaları (Türk
Onkoloji Grubu ortak çalışması). 2. Farmakogenomik Konferansı 26-28 Eylül 2013
Lizbon-Portekiz
2.7.1.16. Kanser ve benzeri kronik hastalıklar sonrası yaşam tarzı değişiklikleri, 29th
Annual Meeting of ARABMED in Europe, 3-6 2013, Berlin Almanya
2.7.1.17. Sözel Sunumlar Oturumu Başkanlığı, 3. Akdeniz Multidisipliner Onkoloji
Forumu toplantısı 24-26 Ekim Atina – Yunanistan
2.7.1.18. Baş Boyun kanseri hastalarına standart tedavi uygulanmasında karşılaşılan
güçlükler, 4th Trends in Head & Neck Oncology, 7-9 Kasım 2013 Dubrovnik
Hırvatistan
2.7.1.19. Hepatosellüler Kanserde K-Ras, African Organization for Research and
Treatment of Cancer 21-24 Kasım 2013, Durban Güney Afrika
2.7.2. Ulusal bilimsel toplantılar:
2.7.2.1. “Meme kanserinin kemik metastazlarının tedavisi”, Türk Kanser ile Savaş
Cemiyeti Toplantısı, İstanbul, Temmuz 1998
2.7.2.2. “Meme kanserinin adjuvan hormon tedavisi”, İstanbul Onkoloji Grubu Meme
Kanseri Konsensus Paneli, İstanbul, Şubat 1999
2.7.2.3. “Rezeke edilmiş akciğer kanserinde adjuvan kemoterapi” İstanbul Onkoloji
Grubu Akciğer Kanseri Konsensus Paneli, İstanbul, Mart 1999
2.7.2.4. “Meme kanseri lokorejyonel relapsının tedavisi” Cerrahpaşa Tıp Fakültesi,
İstanbul, Mayıs 1999.
2.7.2.5. “Over kanserinde optimal adjuvan tedavi” İstanbul Onkoloji Grubu Jinekolojik
Tümörler Konsensus Paneli, İstanbul Mart 2000
2.7.2.6. “Meme kanserinde neo adjuvan kemoterapi”, Gülhane Askeri Tıp Akademisi
Toplantısı, Ankara, Mayıs 2000
2.7.2.7. “HIV Kanserlerine Hemşire Yaklaşımı” Marmara Üniversitesi Onkoloji
Hemşireliği Konferansı, İstanbul, Ekim 2000
44
2.7.2.8. “Küratif rezeke akciğer kanserinde takip” Türk Göğüs Hastalıkları Derneği
İstanbul, Şubat 2001
2.7.2.9. “Rezeke edilmiş küçük hücreli dışı akciğer kanserinde takip” İstanbul Onkoloji
Grubu Akciğer Kanseri Konsensus Paneli, İstanbul, Şubat 2001
2.7.2.10. “Duktal karsinoma insituda adjuvan tamoxifenin rolü” Cerrahpaşa Tıp
Fakültesi Meme Toplantıları İstanbul, Nisan 2001
2.7.2.11. “Meme kanserinde seçici estrojen reseptör modülatörlerinin rolü”, Türk
Meme Cemiyeti, İstanbul, Eylül 2001
2.7.2.12. “HIV kanserlerine hemşire yaklaşımı” Marmara Üniversitesi Tıp Fakültesi
Ulusal Onkoloji Hemşireliği Konferansı, İstanbul, Ekim 2001
2.7.2.13. “Metastatik mesane kanserinin tedavisi” Dr. Lütfi Kırdar Kartal Eğitim ve
Araştırma Hastanesi Tıp Günleri “Onkoloji” İstanbul, Kasım 2001
2.7.2.14. “Meme kanserinin biyolojik tedavileri” Gülhane Askeri Tıp Akademisi
Onkoloji Toplantısı, Ankara, Haziran 2002
2.7.2.15. “Erişkinlerde hodgkin hastalığının tedavisi”, Ulusal Kanser Kongresi,
Antalya, Nisan 2003
2.7.2.16. “Disfajinin kanser hastalarındaki tedavisi”, Türk Onkoloji Grubu Toplantısı,
Ankara, Mayıs 2003
2.7.2.17. “Uluslar arası kanser araştırmalarına katılımdaki güçlükler”, Meme Bilimi
(Senoloji) Derneği, İstanbul, Eylül 2003.
2.7.2.18. “Meme kanserinin sistemik tedavisi”, VII. Ulusal Meme Hastalıkları
Kongresi, Antalya, Ekim 2003
2.7.2.19. “Gastroözafageal kanserlerde süren araştırma projeleri”, Sindirim Sistemi
Kanserleri Çalışma Grubu Toplantısı, İzmir, Aralık 2003
2.7.2.20. “Mide kanserinin adjuvan tedavisi” Türk Onkoloji Grubu Toplantısı, Oturum
başkanlığı, Antalya, Aralık 2003
2.7.2.21. “Kadınlarda sık görülen kanser türleri ve erken tanı” Marmara Üniversitesi,
Hemşirelik Müdürlüğü, 2004 Yılı Hizmet içi Eğitim Programı, İstanbul, Şubat 2004.
2.7.2.22. “Onkolojiye Giriş”, Haydarpaşa Numune Hastanesi Devamlı Eğitim
Toplantıları, İstanbul, Mart 2004
2.7.2.23. “Yüksek riskli gestasyonel trofobilastik tümörlerde kemoterapi”, Türk
Onkoloji Derneği Sürekli Eğitim Toplantıları, Adana, Nisan 2004
2.7.2.24. “Kanser ve mesleki maruziyet” Meslek Hastalıkları ve İş Kazaları Kongresi,
İstanbul, Nisan 2004
2.7.2.25. “HIV ve hodgkin dışı lenfoma”, Türk Pediatrik Onkoloji Kongresi, Kayseri,
Mayıs 2004.
2.7.2.26. “Terminal kanser hastalarında bulantı tedavisi”, Uluslararası Kanser
Hastalarında Palyatif Bakım Kongresi, İstanbul, Eylül 2004.
45
2.7.2.27. “Beslenme ve mide kanseri” Tıbbi Onkoloji Derneği, Mide tümörleri
Sempozyumu” İstanbul, Aralık 2004.
2.7.2.28. “Lokal ileri meme kanserinde güncel tedavi yaklaşımları” İstanbul Tıp
Fakültesi Meme Grubu IX. Mezuniyet Sonrası Eğitim Kursu İstanbul, Aralık 2004.
2.7.2.29. “Primeri bilinmeyen hastaya yaklaşım” XVI. Ulusal Kanser Kongresi.
Antalya, Nisan 2005.
2.7.2.30. “Etiology, pathogenesis, treatment and follow –up” 22. Ulusal
Gastroenteroloji Haftası. Malatya, Eylül 2005
2.7.2.31. “Meme kanseri riskinin değerlendirilmesi ve korunma” VIII. Ulusal Meme
Hastalıkları Kongresi. İstanbul, Eylül 2005
2.7.2.32. “First line chemotherapy in advanced gastric cancer” 1. Ulusal Onkolojik
Araştırmalara çalıştayı ve TOG Alt Çalışma Grupları Toplantısı. Ankara, Aralık 2005
2.7.2.32. “Küçük Hücreli Dışı Akciğer Kanserleri-Lokal İleri Evre, Kemoterapi”
Akciğer, Meme, Gastrointestinal Sistem Kanserlerinde Konsensus Toplantısı.
İstanbul, Mart 2006
2.7.2.33. “Evre II Kolon Kanserinde Adjuvan Kemoterapi Gerekli mi?” I. Tıbbi Onkoloji
Kongresi. Antalya, Mart 2006
2.7.2.34. Bilimsel Kurul. İstanbul Meme Kanseri Konferansı. İstanbul, Eylül 2006.
2.7.2.34. “Disiplinlerin Birbirlerinden Beklentileri” TAKD II. Ulusal Akciğer Kanseri
Kongresi. Antalya, Kasım 2006
2.7.2.35. “Tedavi Uygulamalarına Bağlı Sorunlar” Oturum Başkanı. 5. İstanbul
Üniversitesi Onkoloji Enstitüsü Günleri. Antalya, 30 Kasım – 3 Aralık 2006.
2.7.2.36. “Kolorektal Dışı Gastrointestinal Tümörlerde Hedefe Yönelik Tedaviler” Tıbbi
Onkoloji Derneği, Aralık 2006.
2.7.2.36. “Yeni Prognostik Faktörler ve Hedefe Yönelik Tedaviler” 3. Ulusal Torasik
Onkoloji Kongresi. Marmaris, Haziran 2007.
2.7.2.37. Bilimsel Kurul. 9. Ulusal Meme Hastalıkları Kongresi. .Ankara Eylül 2007
2.7.2.38. Marmara İç Hastalıkları Günleri İstanbul. Onkoloji Oturumu. 29 Şubat 2 Mart
2008
2.7.2.39. Tıbbi Onkoloji Kongresi Antalya. Sözlü Bildiriler. 26-30 Mart 2008
2.7.2. 40. Marmara Üniversitesi Tıp Fakültesi 4. Araştırma Günleri, İstanbul, 2009
2.7.3. Ulusal Bilimsel Toplantılarda Sözlü Bildiriler
2.7.3.1. Turhal NS. Medikal Onkoloji yandal eğitim programlarının standardizasyonu
gerekli(mi)dir? Tıbbi Onkoloji Kongresi Antalya. 26-30 Mart 2008.
2.7.3.2. Yamac D, Turhal S, Karaca B, Coskun HS, Komurcu S, Yavuzsen T, Dane F,
Yaman E, Nalca M, Akmansu M. Kanser tanısını söyleme yöntemimizi sorgulama.
Tıbbi Onkoloji Kongresi Antalya. Sözlü Bildiriler. 26-30 Mart 2008.
46
47
2.8. Düzenleme kurulunda yer alınan bilimsel toplantılar:
2.8.1. Uluslararası
2.8.1.1. Uluslararası Kanser Hastalarında Palyatif Bakım Kongresi, İstanbul, Eylül
2004.
2.8.2. Ulusal
B. Doçentlik SONRASI
2.8.2.1. Marmara Üniversitesi Onkoloji Hemşireliği Konferansı, İstanbul, Ekim 2000
2.8.2.2. Marmara Üniversitesi Tıp Fakültesi Ulusal Onkoloji Hemşireliği Konferansı,
İstanbul, Ekim 2001
2.9. Uluslararası kuruluşlarca yürütülen bilimsel çalışmada esas alınmak üzere
hazırlanmış raporlar:
2.9.1. EORTC European Organization for Research and Treatment of Cancer
Gastrointestinal Tümörler Çalışma Grubu. Metastatik mide kanserinde Docetaxel
Oxaliplatin Capecitabine kombinasyonunun Docetaxel İrinotecan Capecitabine
kombinasyonu ile kıyaslandığı faz II çalışma. 2004
3. BİLİMSEL PROJELERDE YER ALMAK
3.1. Yürütücü olarak yer alınan projeler:
3.1.2. Ulusal
3.1.2.1. Mide kanserli hastaların yaşam kalitesini değerlendirmede EORTC QLQ-C30
ve hastalığa özel anket modülü olan (QLQ-STO 22)' nin güvenirlilik ve gerçekliği
üzerine uluslararası bir saha araştırması, EORTC 15001/40003, Sorumlu
Araştırmacı, 2002.
3.1.2.2. Rezeke edilemeyen karaciğer metastazlı kolorektal kanser hastalarında
irinotekan+fluorouracil/leukovorin kombinasyon tedavisi sonrası rezeke edilebilirlik
hızının değerlendirildiği klinik çalışma, çok merkezli TOD çalışması, Sorumlu
Araştırmacı 2003.
48
3.2. Katılımcı olarak yer alınan projeler:
3.2.1. Uluslararası
3.2.1.1. Çok merkezli yüksek doz infüzyonel 5-FU±Folinik asit ile bolus 5-FU/folinik
asitin karşılaştırıldığı randomize faz III çalışması, EORTC PETACC-2, Marmara
Üniversitesi için Sorumlu Araştırmacı, 2002
3.2.1.2. 35 yaş altı meme tümörlü hastaların adjuvan tedavilere bağlı fertilite kaybı
riskine karşı tutumlarını değerlendirmeye yönelik Uluslararası Meme Grubunun ölçme
çalışması, EORTC 10002, Marmara Üniversitesi için Sorumlu Araştırmacı, 2003.
3.2.1.3. Daha önce tedavi almamış ve platinum ile etoposid verilecek ekstensif evre
küçük hücreli akciğer kanserli hastalarda darbopoetin alfa kullanımının etkisini ölçen
randomize, çift-kör, plasebo kontrollü çalışma, Marmara Üniversitesi için Sorumlu
3.2.1.4. FACT: Anastrozol Monotherapisi ile Anastrozol+Fulvestrant kombinasyonuyla
sağlanan maksimal östrojen blokajının karşılaştırılması: Hormon reseptörü pozitif
meme kanseri olan ve lokalize tümörün primer tedavisinden sonra ilk defa nüks
gelişen postmenapozal kadınlarda yalpan açık, randomize, karşılaştırmalı, çok
merkezli faz III çalışma, Protokol no: 9238SW/0001, Uluslararası, Çok Merkezli
Çalışma, Marmara Üniversitesi için Sorumlu Araştırmacı 2004.
3.2.1.5. Lokal olarak gelişmiş veya metastatik meme kanseri olan postmenapozal
kadınlarda birinci seçenek hormon tedavisinde letrozol ile kombine olarak oral CCI779’a karşı tek başına letrozol uygulamasının karşılaştırıldığı bir faz III randomize
plasebo kontrollü, çift kör çalışma, Protokol no: 3066A1-303-WW, Marmara
Üniversitesi için Sorumlu Araştırmacı, 2004.
3.2.1.6. Menapoz sonrası metastatik meme kanseri hastalarında ilk seçim hormonal
tedavi olarak exemestane ile tamoxifen kullanımının karşılaştırılması, randomize faz
III çalışma, (EORTC Protokol No: 10951) Marmara Üniversitesi için Sorumlu
3.2.1.7. Hormona duyarlı meme kanseri olan premenopozal kadınlarda adjuvan
tedavi olarak over fonksiyonunun baskılanması ve exemestanın rolünü değerlendiren
bir faz III randomiz çalışma. Suppression of ovarian function trial (SOFT), Intergrup
faz III çalışması; IBCSG 24-02, BIG 2-02, EORTC Protokol no 10031), Marmara
Üniversitesi için Sorumlu Araştırmacı, 2004.
3.2.1.8. Post menapozal metastatik meme kanserinde birinci basamak tedavisi olarak
Letrozol ile kemoendokrin tedavisinin eş zamanlı ve sıralı kullanımının Letrozol’ün tek
ajan olarak kullanımıyla karşılaştırıldığı randomize çok merkezli çalışma; CFEM 345
C 2402 Marmara Üniversitesi için Sorumlu Araştırmacı, 2004.
3.2.1.9. Taksanlar ve Antrasiklin terapisinden sonra ilerleyen metastatik meme
kanserli hastalarda 3 haftalık siklüslerde 2 hafta süreyle günde iki defa uygulanan
kapesitabin (Xeloda) tabletleri ile 3 haftada bir IV uygulanan RPR109881’in
karşılaştırıldığı randomize faz III çalışması. Marmara Üniversitesi için Sorumlu
49
3.2.2. Ulusal
3.2.2.1. Daha önce bir veya iki kemoterapi rejimi uygulanmış olan, ancak en son
uygulanan kemoterapi rejimine cevap vermemiş ya da bu rejimi tolere edememiş, ileri
evre, küçük hücreli-dışı akciğer kanserli hastalarda ZD1839 (IressaTM) (250mg tablet)
+ en iyi destek tedavisi kombinasyonunu, plasebo + en iyi destek tedavisi
kombinasyonuyla karşılaştıran, plasebo kontrollü, çok-merkezli, randomize, faz III sağ
kalım çalışması, Iressa/709 (ISEL) çalışması, Yardımcı Araştırmacı, 2003. Puan: 15
3.2.2.2. Adjuvan Kemoradyoterapi Uygulanan Rektum Kanserli Hastalarda Yaşam
Kalitesinin Değerlendirilmesi, Faz IV, Ulusal, Çok Merkezli Çalışma, Yardımcı
3.2.2.3. Haftalık Paclitaxel ve Carboplatin tedavisi almış olan evre IIIA/B, IIIB (plevral
effüzyonlu) ve IV küçük hücreli dışı akciğer kanseri hastalarında Her 2-neu ve TP53
tümör supressör geninin hastaların prognozuna katkıları olup olmadığının
incelenmesi, Yardımcı Araştırmacı, 2004.
3.2.2.4. İndiferansiye ve Non-Keratinize Skuamöz Hücreli Nazofarenks Kanserinde
Dosetaksel-Sisplatin Neoadjuvan Tedavisi Sonrası Kemoradyoterapi Uygulamasının
Etkinliğinin Değerlendirildiği Faz IV Klinik Çalışma, TOG Baş-Boyun Grubu Çalışması,
Ulusal, Çok Merkezli Çalışma, Yardımcı Araştırmacı, 2004.
3.2.2.5. Anastrazol (Arimidex) kullanan erken evre meme kanseri hastalarında
elektronik farmakovijilans çalışması, Yardımcı Araştırmacı, 2004.
3.2.2.6. Taxotere ve Sisplatin ile birinci basamak kemoterapiyi takiben küçük hücreli
olmayan akciğer kanserinin tedavi stratejisine ilişkin gözlem çalışması
XRP6976C/9001 Yardımcı Araştırmacı, 2004.
50

özgeçmiş ve eserler listesi

Transkript

Benzer belgeler

Nazim Serdar Turhal M

Istanbul - ArrivalGuides.com

Istanbul - ArrivalGuides.com

İstanbul

CURRICULUM VITAE Name : Ugur SELEK